An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.
Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
A tumor, basically a carcinoma with a single sarcoma such as leiomyosarcoma or angiosarcoma or multiple sarcomas of uterine origin. The role of estrogen has been postulated as a possible etiological factor in this tumor. (Holland et al., Cancer Medicine, 3d ed, p1703)
Tumors or cancer of the UTERUS.
Excision of the uterus.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.
A malignant epithelial tumor with a glandular organization.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the LIVER.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
A lipid phosphatase that acts on phosphatidylinositol-3,4,5-trisphosphate to regulate various SIGNAL TRANSDUCTION PATHWAYS. It modulates CELL GROWTH PROCESSES; CELL MIGRATION; and APOPTOSIS. Mutations in PTEN are associated with COWDEN DISEASE and PROTEUS SYNDROME as well as NEOPLASTIC CELL TRANSFORMATION.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Dilatation of the cervix uteri followed by a scraping of the endometrium with a curette.
The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Neoplasms containing cyst-like formations or producing mucin or serum.
General term for CYSTS and cystic diseases of the OVARY.
A cell line derived from cultured tumor cells.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
DNA present in neoplastic tissue.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
A multi-functional catenin that participates in CELL ADHESION and nuclear signaling. Beta catenin binds CADHERINS and helps link their cytoplasmic tails to the ACTIN in the CYTOSKELETON via ALPHA CATENIN. It also serves as a transcriptional co-activator and downstream component of WNT PROTEIN-mediated SIGNAL TRANSDUCTION PATHWAYS.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Excision of one or both of the FALLOPIAN TUBES.
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Proteins secreted by the epididymal epithelium. These proteins are both tissue- and species-specific. They are important molecular agents in the process of sperm maturation.
The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Tumors or cancer of the NASOPHARYNX.
Tumors or cancer of the THYROID GLAND.
Tumors or cancer of the human BREAST.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Tumors or cancer of the LUNG.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
Biochemical identification of mutational changes in a nucleotide sequence.
An expression of the number of mitoses found in a stated number of cells.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
Tumors or cancer of the UTERINE CERVIX.
A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells. It is associated with previous pelvic radiation exposure in 20% of patients. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1702)
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Tumors or cancer of the ESOPHAGUS.
Tumors or cancer of the MOUTH.
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A variety of simple repeat sequences that are distributed throughout the GENOME. They are characterized by a short repeat unit of 2-8 basepairs that is repeated up to 100 times. They are also known as short tandem repeats (STRs).
Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.
Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
Tumors or cancer of the COLON.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
Tumors or cancer of the URINARY BLADDER.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
Tumors or cancer of the STOMACH.
Tumors or cancer of the SKIN.
Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
Major constituent of the cytoskeleton found in the cytoplasm of eukaryotic cells. They form a flexible framework for the cell, provide attachment points for organelles and formed bodies, and make communication between parts of the cell possible.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Neoplasms derived from the primitive sex cord or gonadal stromal cells of the embryonic GONADS. They are classified by their presumed histogenesis and differentiation. From the sex cord, there are SERTOLI CELL TUMOR and GRANULOSA CELL TUMOR; from the gonadal stroma, LEYDIG CELL TUMOR and THECOMA. These tumors may be identified in either the OVARY or the TESTIS.
Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.

Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. (1/354)

The primary element in the cAMP signal transduction pathway is the cAMP-dependent protein kinase (PKA). Expression of the RIalpha subunit of type I PKA is elevated in a variety of human tumours and cancer cell lines. The purpose of this study was to assess the prognostic importance of RIalpha expression in patients with ovarian cancer. We have evaluated the expression of RIalpha in a panel of human ovarian tumours (n = 40) and five human ovarian cancer cell lines using quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. The human ovarian cell lines OAW42 and OTN14 express high endogenous levels of RIalpha mRNA and protein (at significantly higher mRNA levels than high tissue expressors, P < 0.05). The ovarian cell line A2780 expresses low endogenous levels of RIalpha mRNA and protein (also at higher mRNA levels than low tissue expressors, P < 0.05). Quantitative RT-PCR revealed no significant difference in RIalpha mRNA expression between different ovarian histological subtypes in this study. No associations were found between RIalpha mRNA expression and differentiation state. RIalpha mRNA expression was significantly associated with tumour stage (P = 0.0036), and this remained significant in univariate analysis (P = 0.0002). A trend emerged between RIalpha mRNA expression levels and overall survival in univariate analysis (P = 0.051), however, by multivariate analysis, stage remained the major determinant of overall survival (P = 0.0001). This study indicates that in ovarian epithelial tumours high RIalpha mRNA expression is associated with advanced stage disease. RIalpha expression may be of predictive value in ovarian cancer and may be associated with dysfunctional signalling pathways in this cancer type.  (+info)

Primary endometrioid carcinoma of fallopian tube. Clinicomorphologic study. (2/354)

Twenty cases of primary Fallopian tube endometrioid carcinoma (PFTEC) are presented in the paper. This accounts for 42.5% of all histologic forms of primary Fallopian tube carcinoma (PFTC) found in our Department. The youngest patient was 38, and the oldest 68 years (mean: 56 years). Seven patients were nulliparas. Only two cases were bilateral. According to FIGO staging, 13 cases were evaluated as stage I, 4 as II, and 3 as stage III. Due to the histologic grading, 8 tumors were classified as well, 7 as moderately, and 5 as poorly differentiated. In the time of preparation of the manuscript, 12 women were still alive, 2 of them with recurrent disease. The follow-up of patients without recurrence ranged from 4 to 120 months (median: 63). Eight patients had died (survival time: from 4 to 65 months; median: 26). Metastases were found in 8 patients, especially to ovaries. In 14/20 cases of PFTEC various forms of tubal wall invasion were observed. Blood or lymphatic vessels involvement was found in 9 patients. Six of them had died and one is alive with the symptoms of disease. Immunohistochemical detection of the mutant form of p53 protein and oncogene product, c-erbB-2, was studied in 17 cases. Nine patients exhibited simultaneous p53 protein accumulation and c-erbB-2 expression. 2/9 of these patients are alive with recurrent tumors and 4/9 died. Endometrioid carcinoma of the Fallopian tube can be characterized by a tendency to superficial invasion of tubal wall and in a half of the cases by invasion of vessels. The majority of these tumors were diagnosed at an early stage tumors.  (+info)

Clear cell carcinoma arising in a Cesarean section scar endometriosis: a case report. (3/354)

Endometriosis of a surgical scar is rare and occurs mainly when a hysterectomy or Cesarean section was performed. We describe a 54-year-old woman with a large suprapubic mass as a definite case of a endomerioid carcinoma developing within the scar endometriosis following Cesarean section. Scar endometriosis, as well as endometriosis at other sites, can turn malignant. Endometrioid carcinoma is the most common histological pattern of malignant tumor arising in endometriosis. But clear cell carcinoma is very unusual. A case of primary clear cell carcinoma in endometriosis of a Cesarean section scar is described. To the best of our knowledge, this is the first documented case of endomerioid carcinoma developing within the scar endometriosis in Korea.  (+info)

Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer. (4/354)

Abnormalities in the function of receptor tyrosine kinases (RTKs) have been demonstrated to be important in the pathogenesis of cancer. H-Ryk, a new member of the RTK family, is an unusual RTK in that it is catalytically inactive because of amino acid substitutions of conserved residues in the catalytic domain. We show by immunohistochemistry that it is expressed in the epithelium, stroma, and blood vessels of normal tissues. Evaluation of a panel of 33 primary ovarian tumors (2 benign, 8 borderline, and 23 malignant) was performed. H-Ryk was overexpressed in borderline and malignant ovarian tumors. In serous and clear cell subtypes, there was increased expression in the epithelium, stroma, and blood vessels. Consistent with this observation, overexpression of H-Ryk in the mouse fibroblast cell line NIH3T3 induces anchorage-independent growth and tumorigenicity in nude mice. This implies that overexpression of the receptor can be transforming and may therefore be significant in the pathogenesis of ovarian cancer.  (+info)

beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. (5/354)

The immunohistochemical expression pattern of beta-catenin has been correlated with beta-catenin gene mutations, clinicopathological features, and disease outcome in 69 stage I and II ovarian carcinomas. beta-Catenin expression was localized in the nuclei, in addition to the cytoplasm and membrane, in 11 tumors (16%): nine endometrioid carcinomas with widespread nuclear expression and two serous carcinomas with focal nuclear expression. The remaining 58 carcinomas (84%) only had membranous beta-catenin expression. All but one of the endometrioid carcinomas with nuclear beta-catenin expression had considerable squamous metaplasia, and five of these cases had large areas of endometrioid tumor of low malignant potential. In addition, beta-catenin nuclear expression was observed in atypical epithelial cells in endometriotic glands adjacent to an endometrioid carcinoma. Sequencing was performed on 25 tumors and corresponding normal tissue: all 13 endometrioid tumors as well as 12 carcinomas of other histological types (four serous, two clear cell, two mucinous, and two mixed). There were oncogenic mutations in the phosphorylation sequence for GSK-3beta in exon 3 of the beta-catenin gene in seven endometrioid carcinomas with beta-catenin nuclear expression. Three mutations affected codon 32 (D32G, D32Y, and D32Y), one affected codon 33 (S33C), two affected codon 37 (S37C and S37F), and one affected codon 41 (T41A). No mutations were observed in the other 18 carcinomas analyzed, comprising two endometrioid and two serous carcinomas with beta-catenin nuclear expression, and 14 carcinomas of different histological types with only membranous expression. In the univariate and multivariate survival analyses, beta-catenin nuclear expression was selected as an indicator of good prognosis, because no patient whose tumor expressed beta-catenin in the nuclei showed relapses or died, in contrast to the 19 relapses and deaths among patients with tumors that only had beta-catenin membranous expression, including three of the four patients with endometrioid carcinomas. Oncogenic beta-catenin mutation is characteristic of a group of endometrioid carcinomas with a good prognosis, most of which originate from previous benign or borderline lesions. Endometrioid carcinomas with exclusively membranous expression of beta-catenin seem to represent a different subgroup of carcinomas that probably have a worse prognosis. In early-stage ovarian cancer, determination of the beta-catenin expression pattern could prove to be a useful marker for selecting low-risk patients.  (+info)

Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*. (6/354)

Most of the ovarian cancers originate from the ovarian surface epithelium derived from the coelomic mesothelium. The Met proto-oncogene encodes a transmembrane tyrosine kinase receptor (Met) that has the capacity to regulate cell proliferation and differentation and it is activated by hepatocyte growth factor. Trisomy of chromosome 7 and Met protein overexpression have been were observed in ovarian carcinomas, the papillary renal cancers and other solid tumors. Frequent mutations of Met proto-oncogene have been found in hereditary papillary renal cancer (HPRC) and most of the mutations are located in the tyrosine kinase domain. The aim of this study to perform a mutation analysis of exons 17 19 of Met proto-oncogene in epithelial ovarian tumors (EOTs). We have examined 24 tumor samples from patients, operated with EOTs. Mutation was detected in exon 18 in only one sample of 24 EOTs. Our results indicate that mutations located in the Met proto-oncogene is not a common event in EOT. It is not clear whether the mutation plays a role in the tumorigenesis or progression of EOT or not.  (+info)

Hormone replacement therapy and risk of epithelial ovarian cancer. (7/354)

It has been suggested that oestrogen replacement therapy is associated with risk of epithelial ovarian cancer of the endometrioid type. Using data from an Australian population-based case-control study, the relation between unopposed oestrogen replacement therapy and epithelial ovarian cancer, both overall and according to histological type, was examined. A total of 793 eligible incident cases of epithelial ovarian cancer diagnosed from 1990 to 1993 among women living in Queensland, New South Wales and Victoria were identified. These were compared with 855 eligible female controls selected at random from the electoral roll, stratified by age and geographic region. Trained interviewers administered standard questionnaires to obtain detailed reproductive and contraceptive histories, as well as details about hormone replacement therapy and pelvic operations. No clear associations were observed between use of hormone replacement therapy overall and risk of ovarian cancer. Unopposed oestrogen replacement therapy was, however, associated with a significant increase in risk of endometrioid or clear cell epithelial ovarian tumours (odds ratio (OR) 2.56; 95% confidence interval (CI) 1.32-4.94). In addition, the risk associated with oestrogen replacement therapy was much larger in women with an intact genital tract (OR 3.00; 95% CI 1.54-5.85) than in those with a history of either hysterectomy or tubal ligation. Post-menopausal oestrogen replacement therapy may, therefore, be a risk factor associated with endometrioid and clear cell tumours in particular. Additionally, the risk may be increased predominantly in women with an intact genital tract. These associations could reflect a possible role of endometriosis in the development of endometrioid or clear cell ovarian tumours.  (+info)

A case-control study of galactose consumption and metabolism in relation to ovarian cancer. (8/354)

Consumption or metabolism of dairy sugar and ovarian cancer have been linked based on evidence that galactose may be toxic to ovarian germ cells and that ovarian cancer is induced in animals by depletion of oocytes. We assessed consumption of dairy products and obtained blood for biochemical and molecular genetic assessment of galactose metabolism in 563 women with newly diagnosed epithelial ovarian cancer and 523 control women selected either by random digit dialing or through lists of residents in eastern Massachusetts and New Hampshire. We observed no significant differences between cases and controls in usual consumption of various types of dairy products or total daily lactose (the principal source of galactose in the diet); nor did we find that RBC activity of either galactose-1-phosphate uridyl transferase (GALT) or galactokinase differed. The mean (and SE) activity of uridine diphospho-galactose 4'-epimerase (in micromoles per hour per gram of hemoglobin) was, however, significantly lower (P < 0.005) in cases compared with controls, 20.32 (0.31) versus 21.64 (0.36). Ovarian cancer cases were also more likely to carry the N314D polymorphism of the GALT gene, generally predisposing to lower GALT activity. The difference was most evident for endometrioid and clear cell types of ovarian cancer, in which 3.9% of cases were found to be homozygous for N314D compared with 0.4% of controls, yielding an odds ratio and 95% confidence interval of 14.17 (2.62-76.60). We conclude that, whereas adult consumption of lactose carries no clear risk for the disease, certain genetic or biochemical features of galactose metabolism may influence disease risk for particular types of ovarian cancer.  (+info)

Mutations of NH2-terminal β-catenin sequences have been demonstrated in various human tumor types, including colorectal carcinomas (24 , 39) , melanomas (40) , hepatoblastomas (41) , medulloblastomas (42) , prostatic carcinomas (43 , 44) , and uterine endometrial carcinomas (45, 46, 47, 48) , particularly endometrioid adenocarcinomas with squamous differentiation (10) . Prior studies of ovarian carcinomas have indicated that β-catenin mutations are common only in OEAs, with estimated mutation frequencies of 16-54% (10, 11, 12, 13, 14) .. We have pursued our studies of the prevalence and mechanisms underlying β-catenin deregulation in 45 histologically verified frozen primary OEA tissues. This is, in fact, a substantial number of primary tumors of this particular histological subtype, because only 10-20% of ovarian carcinomas are endometrioid (49) . We identified CTNNB1 exon 3 mutations in 31% of our primary ovarian endometrioid carcinomas. Mutations inactivating the APC, AXIN1, and AXIN2 ...
Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third of cases have focal squamous differentiation. They are part of the surface epithelial tumor group of ovarian neoplasms (10-20% of which are the endometrioid type). Benign and borderline variants are rare, as the majority are malignant. There is an association with endometriosis and concurrent primary endometrial carcinoma (endometrial cancer). On gross pathological examination, the tumor is cystic and may be solid and some arise in cystic endometriosis. In 40% of cases, endometrioid tumors are found bilaterally. Endometrioid carcinoma can also arise in the endometrium. Grades 1 and 2 are considered type 1 endometrial cancer, while grade 3 is considered type 2. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN gene mutation profiles. PTEN mutations are more frequent in low-grade endometrial endometrioid carcinomas (67%) compared with ...
Endometrial cancer is one of the most common malignancies of the reproductive female tract, with endometrioid endometrial cancer being the most frequent type. Despite the relatively favourable prognosis in cases of endometrial cancer, there is a necessity to evaluate clinical and prognostic utility of new molecular markers. MiRNAs are small, non-coding RNA molecules that take part in RNA silencing and post-transcriptional regulation of gene expression. Altered expression of miRNAs may be associated with cancer initiation, progression and metastatic capabilities. MiRNA-205 seems to be one of the key regulators of gene expression in endometrial cancer. In this study, we investigated clinical and prognostic role of miRNA-205 in endometrioid endometrial cancer. After total RNA extraction from 100 archival formalin-fixed paraffin-embedded tissues, real-time quantitative RT-PCR was used to define miRNA-205 expression levels. The aim of the study was to evaluate miRNA-205 expression levels in regard to
We encountered two cases of endometrioid carcinoma of uterus with extensive surface epithelial changes (SECs) mimicking serous borderline tumor (SBT) of the ovary. The first case was a well-differentiated endometrioid carcinoma arising in a background of complex atypical hyperplasia. The second case was moderately-differentiated endometrioid carcinoma with squamous and mucinous differentiation. The SECs comprised of thin microapapillae without hierarchal branching, lined by cuboidal cells with eosinophilic cytoplasm and mild to moderate nuclear atypia. These areas were reminiscent of SBTs of ovary, micropapillary type. This report expands the existing spectrum of SECs. Serous borderline tumor of ovary like surface epithelial changes could be misleading if present in an endometrial biopsy or curettings. Therefore, knowledge of this morphologic variation is important.
OBJECTIVE We previously described vascular invasion-associated changes, defined as the presence of vascular invasion or perivascular lymphocytic infiltrates, as key prognostic indicators in stage I endometrioid carcinoma. The current study was undertaken to examine the prognostic value of HER-2/neu expression in relation to other factors, including vascular invasion-associated changes, in surgical stage I endometrioid carcinoma. STUDY DESIGN Seventy-one patients with surgical stage I endometrioid carcinoma treated by hysterectomy and followed up were randomly chosen for retrospective analysis of prognostic indicators including standard clincopathologic features, deoxyribonucleic acid ploidy, and HER-2/neu expression. The latter was examined by an objective computerized quantitative immunohistochemical system. RESULTS By univariate analysis many factors were found to correlate with outcome, including age, tumor grade, depth of invasion, ploidy, HER-2/neu expression, and vascular invasion-associated
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. ...
In endometrioid cancer cases, the depth of myometrial invasion, the lymphovascular space invasion (LVSI) and the microcystic, elongated, and fragmented (MELF) glands type of invasion are predictors for a metastasis. Although the intermediate grade papillary endometrioid adenocarcinoma of the endometrium is currently not included in the latest classification of the tumors in the female reproductive system, its existence provokes an interest due to the necessity to perform differential diagnosis against other endometrioid tumors. Hereby presented is a case of papillary endometrioid carcinoma of intermediate grade with invasion in leiomyoma, expressed via LVSI and MELF syndrome with intact myometrium. Morphological and immunohistochemical algorithms have been performed.
TY - JOUR. T1 - Description of an endometrioid ovarian cancer cell line. AU - Giancotti, Francesca R.. AU - Dorsett, Brent H.. AU - Weaver, Scott. AU - Bharathur, Rajendra. AU - Ioachim, Harry L.. AU - Barber, Hugh R K. PY - 1989. Y1 - 1989. N2 - A human cell line, designated L-1, has been established from the ascites of an untreated patient with stage IV (FIGO) endometrioid ovarian cancer. This cell line initially grew uninterrupted for 6 months without fibroblast contamination and contact inhibition, and has been subcultured weekly for the past 7 years. L-1 does not contain steroid hormone receptors nor does it demonstrate the presence of oncofetal antigens by immunohistochemical techniques. The doubling time of L-1 is 11.8 hr. Flow cytometric analysis reveals an aneuploid DNA peak, and an abnormal karyotype demonstrates hyperdiploidy, translocations, and deletions. Morphology, growth patterns, cytogenetic analysis, and other features of L-1 are characterized.. AB - A human cell line, ...
Devor EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, Lankes HA, Thaker P, Argenta PA, Pearl ML, Zweizig SL, Mannel RS, Brown A, Ramirez NC, Ioffe OB, Park KJ, Creasman WT, Birrer MJ, Mutch D, Leslie KK. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 12; 147(3):648-653 ...
Endometriosis-associated ovarian clear cell carcinomas (OCCC) and ovarian endometrioid carcinomas (OEC) are the second and third most common histologic subtypes that together account for approximately 25% of the epithelial ovarian cancer cases. OCCC ranks second as the cause of death from epithelial ovarian cancer and is associated with a poorer prognosis compared with other ovarian cancer subtypes (7). OCCC typically has a low response rate to platinum-based standard care for ovarian cancer. Radiotherapy is potentially beneficial for a subset of OCCC. However, for advanced stage disease, there is currently no effective therapy. Notably, in Japan, its prevalence is higher than in western countries, with an estimated incidence of approximately 25% of epithelial ovarian cancer.. On the basis of saturation of mutational analysis of TCGA datasets, ARID1A is the most frequently mutated epigenetic regulator across human cancers (3). OCCC and OEC are among the types of cancer with highest ARID1A ...
TY - JOUR. T1 - p53 Overexpression and bcl-2 persistence in endometrial carcinoma. T2 - Comparison of papillary serous and endometrioid subtypes. AU - Zheng, Wenxin -. AU - Cao, Peiqin. AU - Zheng, Mei. AU - Kramer, Elmer E.. AU - Godwin, Thomas A.. PY - 1996/5. Y1 - 1996/5. N2 - Forty-two cases, including 21 uterine papillary serous carcinomas (UPSC) and 21 age-, nuclear-grade-, and clinical-stage-matched uterine endometrioid carcinomas (UEC), were studied immunohistochemically for p53 and bcl-2 in archival paraffin-embedded tissue. Compared to UEC (28.6% positive), UPSC (71.4% positive) had a significantly higher frequency of p53 overexpression (P = 0.005); furthermore, in a clinical-stage-matched fashion, a higher frequency of p53 overexpression was found in early-stage cases (P = 0.032), but not in late-stage cases. In a nuclear-grade-matched comparison, no statistical difference in p53 overexpression was identified between the two subtypes, although UPSC had stronger p53 immunoreactivity ...
This randomized phase II trial studies how well medroxyprogesterone acetate with or without entinostat before surgery works in treating patients with endometrioid endometrial cancer. Medroxyprogesterone acetate is a progesterone, a hormone produced by body normally. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Given medroxyprogesterone acetate with or without entinostat may work better in treating patients with endometrioid endometrial cancer.. ...
malissatench - Patient: Endometrial (Uterine) Cancer > Endometrioid Adenocarcinoma > Poorly Differentiated Carcinoma Patient Info: Receiving hospice or palliative care, Diagnosed: over 11 years ago, Female, Age: 34
TY - JOUR. T1 - Endometrioid adenocarcinoma arising from adenomyosis after black cohosh with St Johns wort. AU - Bae, H. S.. AU - Kim, I. S.. AU - Kang, J. S.. AU - Song, J. Y.. PY - 2014/2. Y1 - 2014/2. UR - http://www.scopus.com/inward/record.url?scp=84893111976&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84893111976&partnerID=8YFLogxK. U2 - 10.3109/01443615.2013.859240. DO - 10.3109/01443615.2013.859240. M3 - Article. C2 - 24456461. AN - SCOPUS:84893111976. VL - 34. SP - 213. EP - 214. JO - Journal of Obstetrics and Gynaecology. JF - Journal of Obstetrics and Gynaecology. SN - 0144-3615. IS - 2. ER - ...
ProScis uterus tissue slide Endometrioid Adenocarcinoma can be used with any antibody shown to be effective in formalin-fixed tissue using a standard immunostaining protocol.
Phosphorylation of histone H2AX (gammaH2AX) is a sensitive marker of DNA damage, particularly induction of DNA double-strand breaks. Using multiparameter cytometry we explored the effects of doxorubicin (DOX), cisplatin (CDDP) and 5-fluorouracil (5-FU) on four types of endometrioid adenocarcinoma ce …
5219 Insulin growth factor binding protein-3 (IGFBP-3) has been postulated to be a mediator of growth suppression signal. In our previous study, IGFBP-3 was found as an invasion suppressor gene in ovarian endometrioid carcinoma (EC) (Oncogene 2007, on line). Since promoter methylation can silence gene expression, we investigated whether hypermethylation of the IGFBP-3 promoter is involved in the loss of IGFBP-3 expression in ovarian EC. By methylation-specific PCR assay, IGFBP-3 promoter was found methylated in the higher invasive ovarian cancer cell line OVTW59-P4, compared with the lower invasive P0 cell line. After treatment with DNA methyltransferase inhibitor 5-aza-2-deoxycytidine, P4 showed restoration of IGFBP-3 expression. Methylation status correlated with IGFBP-3 mRNA and protein levels. By bisulfite genomic DNA sequencing, the hyprermethylated CpG sites were found focused at the -210, -206, -183 and -179 sites of p53 consensus binding sequence in IGFBP-3 promoter region. A luciferase ...
Clinical trial for Complex Endometrial Hyperplasia With Atypia | Grade 1 Endometrial Endometrioid Adenocarcinoma , Improving the Treatment for Women With Early Stage Cancer of the Uterus
miRNAs have been implicated in inflammation, fibrosis, EMT and various types of cancers, such as oral cancer. Some miRNA families have gained attention for their clear function in tissue fibrosis. miR-30c has been reported to be a tumor suppressor in endometrial cancer (14) and to act as an independent predictor for the clinical benefit of tamoxifen therapy in patients with advanced breast cancer (15). A previous study showed that miR-206 overexpression inhibited estrogen receptor-α-dependent proliferation, impaired invasiveness and induced cell cycle arrest of estrogen receptor-α-positive endometrial endometrioid adenocarcinoma cell lines (16). miR-203 has previously been shown to play an important role in epithelial cell biology (17). miR-203 was differentially regulated in gingival epithelial cells in the presence of P. gingivalis. Silencing of miR-203 diminished the activation of signal transducer and activator of transcription 3 (Stat3), suggesting that alterations in miRNAs modulate ...
TY - JOUR. T1 - Risk factors for recurrence and prognosis of low-grade endometrial adenocarcinoma; Vaginal versus other sites. AU - Moschiano, Elizabeth J.. AU - Barbuto, Denise A.. AU - Walsh, Christine. AU - Singh, Kanwaljit. AU - Euscher, Elizabeth D.. AU - Roma, Andres A.. AU - Ali-Fehmi, Rouba. AU - Frauenhoffer, Elizabeth E.. AU - Montiel, Delia P.. AU - Kim, Insun. AU - Djordjevic, Bojana. AU - Malpica, Anais. AU - Hong, Sung Ran. AU - Silva, Elvio G.. PY - 2014/5. Y1 - 2014/5. N2 - Endometrial adenocarcinoma is the most common gynecologic cancer in the United States. The prognosis is generally favorable, however, a significant number of patients do develop local or distant recurrence. The most common site of recurrence is vaginal. Our aim was to better characterize patients with vaginal recurrence of low-grade endometrioid adenocarcinoma with respect to associated tumor parameters and clinical outcome. We compiled 255 cases of low-grade (FIGO Grade I or II) endometrioid adenocarcinoma on ...
Endometrial cancer (EC) is the sixth most frequently diagnosed cancer among women worldwide [ 1 ]. The incidence of EC is higher in high-income …
OBJECTIVE The purpose of this study was to evaluate the role of surgical staging in patients with grade 1 endometrioid uterine cancer. STUDY DESIGN Data were extracted from Surveillance, Epidemiology, and End Results Program from 1988 to 2001. Kaplan-Meier and Cox proportional hazards analyses were used to determine predictors for disease-specific survival. RESULTS Twelve thousand seven hundred and twelve women were reported with endometrioid carcinoma, including 3867 with grade 1 disease, of which 25.5% had stage IC or more advanced disease, 15.4% with disease extending beyond the uterine corpus, 7.3% with extrauterine metastases, and 3.3% with lymph node metastases. On multivariate analysis, younger age and earlier stage remained as significant prognostic factors for improved survival. CONCLUSION Since grade 1 endometrioid uterine cancers have a 15.4% risk of extrauterine spread, a complete surgical staging procedure is recommended when clinically feasible. Younger age and earlier stage are
Currently, uveal melanoma is not considered within the Lynch syndrome tumor spectrum. However, there are studies suggesting a contribution of microsatellite instability in sporadic uveal melanoma tumorigenesis. We report a 45-year-old woman who was referred for genetic counseling due to a family history of Lynch syndrome caused by a MLH1 mutation. She originally underwent enucleation (removal) of the right eye secondary to a uveal spindle cell melanoma diagnosed at age 25. The tumor recurred 22 years later presenting as an ovarian metastasis and concurrently a microscopic endometrial endometrioid carcinoma, grade 1/3 was diagnosed. Subsequent studies highlighted that the uveal melanoma showed high microsatellite instability and loss of MLH1 and PMS2 protein expression, with no MLH1 promoter methylation or BRAF mutation. Additionally, a GNAQ mutation was found. We conclude that our patients uveal melanoma is most likely related to MLH1 germline mutation and thus Lynch syndrome related. To the ...
Hyperactivation of the canonical Wnt/β-catenin pathway, caused by mutations in such components as β-catenin and APC, is one of the most frequent signaling abnormalities in several human cancers including colorectal carcinomas (15), melanomas (16), hepatoblastomas (17), medulloblastomas (18), prostatic carcinomas (19), and uterine and ovarian endometrioid adenocarcinomas (10, 20-22). In breast cancer, however, evidence of comparable mutations is surprisingly lacking (23). In contrast, there is strong evidence, based on immunohistochemical analyses, that the Wnt/β-catenin pathway is activated (23-25). Importantly, aberrant β-catenin expression in breast cancer is associated with poor clinical outcome (23-26). Metaplastic carcinomas have never been analyzed for Wnt pathway gene mutations.. Because breast carcinoma arises from glandular epithelium, it usually exhibits the features of an adenocarcinoma. However, in some cases, part or all of the neoplastic cells differentiate into a nonglandular ...
This is a multi-center, open-label, randomized, parallel group two-stage phase 1 study with a phase 2 expansion component in pts with recurrent or metastatic APRpos uterine endometrioid adenocarcinoma. Stage 1: Six dose cohorts, 5 using the extended release tablet (ER) formulation (10 mg BID, 20 mg BID, 30 mg BID, 40 mg BID, 50 mg BID) and 1 using the immediate-release (IR) tablet formulation 100 mg QD will be randomized in parallel. After enrollment of 36 patients in Stage 1, a dose of 50 mg BID was determined to be the RP2D. Stage 2: An additional 10 patients with recurrent or metastatic APRpos uterine endometrioid adenocarcinoma (Stage 2a) will be enrolled at the RP2D. Based on the response in Stage 2a, the cohort will be further expanded by up to 19 more patients to a total of 29 patients to confirm the efficacy and safety profile of onapristone in this selected patient population (Stage 2b ...
臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。. To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of NTU Repository with Academic Hub to form NTU Scholars.. ...
TY - JOUR. T1 - PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia. AU - Strickland, Amanda L.. AU - Rivera, Glorimar. AU - Lucas, Elena. AU - John, George. AU - Cuevas, Ileana. AU - Castrillon, Diego H.. N1 - Funding Information: Supported by CPRIT grant RP160211 to D.H.C. Research reported in this publication was also supported by the National Cancer Institutes of the National Institutes of Health under award number 5P30CA142543. The authors declare no conflict of interest.. PY - 2019/11/1. Y1 - 2019/11/1. N2 - The diagnosis of endometrioid intraepithelial neoplasia (EIN) is challenging owing to limited sampling, hormonal status, and other confounding histologic variables. Markers such as PTEN or PAX2 can delineate EIN in some cases, but are not wholly reliable. Clearly, new markers of EIN are needed. We explored several potential markers of EIN based rationally on molecular pathways most frequently misregulated in endometrial cancer: the ...
This prospective study examined several aspects of the relationship between BMI and endometrial cancer in postmenopausal women from the United States. First, among never-users of postmenopausal HT, the positive association between body mass and endometrial cancer was monotonic across the entire range of BMI examined, with a 51% reduction in risk among the leanest women and a 441% increase in risk among the heaviest women. Secondly, use of E + P HT modified the association between BMI and endometrial cancer. BMI was not significantly related with risk among women who had used E + P. Obesity was associated with a greater risk of both type I and type II endometrial cancers, although the association with type II cancers was driven by high-grade endometrioid tumors; the small number of cases with serous, clear cell, and papillary histology precluded meaningful analysis using this stricter definition.. Most of the 57 case-control and 24 prospective cohort analyses published to date (6, 8, 31-33) show ...
Synchronous endometrial and ovarian (SEO) carcinomas involve endometrioid neoplasms in both the ovary and uterus at the time of diagnosis. Patients were traditionally classified as having independent primary SEO lesions or as having metastatic endometrioid carcinoma. Recent studies have supported that SEO tumors result from the dissemination of cells from one organ site to another. However, whether this can be considered a metastasis or dissemination remains unclear. In this report, we performed whole-exome sequencing of tumor samples from a woman with well-differentiated endometrioid SEO tumors and a clinical recurrent poorly differentiated peritoneal tumor that was diagnosed 8 years after the complete resection of the SEO tumors ...
Objectives Endometrioid carcinoma of the ovary is one of the most types of epithelial ovarian cancer associated to endometrioisis. Endometrioid tumors as well as endometriotic implants are...
Weve invested more than $4.9 billion in cancer research since 1946, all to find more - and better - treatments, uncover factors that may cause cancer, and improve cancer patients quality of life. Instead, it groups cancers into localized, regional, and distant stages: (Based on people diagnosed with endometrial cancer between 2009 and 2015. ), *SEER= Surveillance, Epidemiology, and End Results, The American Cancer Society medical and editorial content team. Due to this notion, every patient and even non-patient will not like to reach this kind of stage. For patients with FIGO Stage IA, IB, and IC UPSC who underwent complete surgical staging, the 5-year actuarial DFS by depth of myometrial invasion was 100, 71, and 40%, respectively (p = 0.006). For example, endometrioid carcinomas have a more favourable prognosis than serous adenocarcinomas. Stage: 3 Survival Rate: 30 percent. We couldnt do what we do without our volunteers and donors. Making Strides Against Breast Cancer Walks, Common ...
Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1 Using a connectivity map, the authors identified prostaglandin E1 as a small molecule that partly elicited the gene expression changes in leukemic stem cells caused by Tcf1/Lef1 deficiency. [Cell Stem Cell] Abstract , Graphical Abstract CD55 Regulates Self-Renewal and Cisplatin Resistance in Endometrioid Tumors Effective targeting of CSCs requires neutralization of self-renewal and chemoresistance, but these phenotypes are often regulated by distinct molecular mechanisms. Investigators report the ability to target both of these phenotypes via CD55, an intrinsic cell surface complement inhibitor, which was identified in a comparative analysis between CSCs and non-CSCs in endometrioid cancer models. [J Exp Med] Full Article Effective Treatment of Drug Resistant Recurrent Breast Tumors Harboring Cancer Stem-Like Cells by Staurosporine/Epirubicin Co-Loaded Polymeric ...
Cancer cell lines have been, and will continue to be, important tools in oncology research, but there are major limitations in the fidelity of existing cell lines as a model of human cancers. Therefore, the aim of our study was to generate and characterize patient-specific cell lines from solid tumors that more faithfully recapitulate the primary tumor genetic and morphologic characteristics.. We performed cell line derivation on a primary human breast adenocarcinoma (ER+/PR+/HER2-), a lung adenocarcinoma, a high-grade serous ovarian carcinoma, and an endometrioid ovarian carcinoma procured from a commercial tissue bank. Portions were snap-frozen for molecular analysis, and the remainder was minced and processed for cell culture. Cells were cultured and the resulting monolayer was stained by immunocytochemistry with a pan-keratin antibody for the presence of epithelial cells. Any contaminating fibroblasts were removed. We extracted DNA from the resulting breast and lung cancer cell lines at low, ...
BARRETA, AMILCAR... Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis. HUMAN PATHOLOGY 85 n. p. 72-81 MAR 2019. Journal article.
Malignant neoplasms involving the uterus account for a significant proportion of all female cancers. They can be classified as: endometrial carcinoma : commonest: |90% of all uterine malignancies endometrioid carcinoma of the uterus: commonest...
Arian CSCs include CD44, epithelial cell adhesion moleculeHuang et al. BMC Cancer (2015) 15:Page 6 ofTable 3 The associations of ALDH1 expression levels in stromal cells and the clinical and pathologic characteristicsALDH1 IHC score in stromal cells 1 (negative) Number Age (years old): 39 40?9 50?9 60?9 70 missing Histological subtype: Serous carcinoma Mucinous carcinoma Endometrioid carcinoma Cle
Toda la información sobre las últimas publicaciones científicas de la Clínica Universidad de Navarra. Agreement between preoperative transvaginal ultrasound and intraoperative macroscopic examination for assessing myometrial infiltration in low risk endometrioid carcinoma of the endometrium
Powered by Pure, Scopus & Elsevier Fingerprint Engine™ © 2021 Elsevier B.V. We use cookies to help provide and enhance our service and tailor content. By continuing you agree to the use of cookies. ...
以下に掲載:Cancer Science 105 pp.1307-1312 2014. Japanese Cancer Association 共著者:Eiichi Kato, Makoto Orisaka, Tetsuji Kurokaw
Looking for online definition of endometrioid carcinoma in the Medical Dictionary? endometrioid carcinoma explanation free. What is endometrioid carcinoma? Meaning of endometrioid carcinoma medical term. What does endometrioid carcinoma mean?
We evaluated the efficacy and safety of the aromatase inhibitor exemestane in patients with advanced, persistent or recurrent endometrial carcinoma. We performed an open-label one-arm, two-stage, phase II study of 25 mg of oral exemestane in 51 patients with advanced (FIGO stage III-IV) or relapsed endometrioid endometrial cancer. Patients were stratified into subsets of estrogen receptor (ER) positive and ER negative patients. Recruitment to the ER negative group was stopped prematurely after 12 patients due to slow accrual. In the ER positive patients, we observed an overall response rate of 10%, and a lack of progression after 6 months in 35% of the patients. No responses were registered in the ER negative patients, and all had progressive disease within 6 months. For the total group of patients, the median progression free survival (PFS) was 3.1 months (95% CI: 2.0-4.1). In the ER positive patients the median PFS was 3.8 months (95% CI: 0.7-6.9) and in the ER negative patients it was 2.6 months (95%
Thank you for sharing this Cancer Prevention Research article.. NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.. ...
Ovarian malignancy was found to be associated with ovarian, laryngeal, breast, endometrial, liver, and colon carcinoma, as well as myeloma; epithelial ovarian malignancy was found to be associated with ovarian, endometrial, and skin malignancies and with melanoma and myeloma; papillary serous cystadenocarcinoma was found to be associated with ovarian and skin malignancies and with myeloma; and endometrioid carcinoma was found to be associated with endometrial, ovarian, and prostate malignancies and with melanoma. For younger women (ages 40-45 years) whose mothers were affected with endometrial malignancies, the risk of developing endometrioid carcinoma was slightly greater than the risk of developing papillary serous cystadenocarcinoma. ...
TY - JOUR. T1 - Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy. AU - Ikeda, Yuji. AU - Oda, Katsutoshi. AU - Ishihara, Hideki. AU - Wada-Hiraike, Osamu. AU - Miyasaka, Aki. AU - Kashiyama, Tomoko. AU - Inaba, Kanako. AU - Fukuda, Tomohiko. AU - Sone, Kenbun. AU - Matsumoto, Yoko. AU - Arimoto, Takahide. AU - Maeda, Daichi. AU - Ikemura, Masako. AU - Fukayama, Masahi. AU - Kawana, Kei. AU - Yano, Tetsu. AU - Aoki, Daisuke. AU - Osuga, Yutaka. AU - Fujii, Tomoyuki. PY - 2015/11/17. Y1 - 2015/11/17. N2 - Background:Pathologically low-risk endometrial cancer patients do not receive postoperative treatment; however, 10-15% of these patients show recurrence with poor prognosis. We evaluated the clinical importance of cyclin-dependent kinase 4/6 (CDK4/6) activity, and its significance as a novel biomarker for the prognosis and chemo-sensitivity of endometrioid endometrial carcinoma ...
Laparoscopic resection of endometrioid ovarian cyst (chocolate cysts, endometriomas) (costs for program #52025) ✔ Alfried Krupp Hospital in Essen-Ruettenscheid ✔ Department of Gynecology and Obstetrics ✔ BookingHealth.com
Laparoscopic resection of endometrioid ovarian cyst (chocolate cysts, endometriomas) (costs for program #251613) ✔ University Hospital Erlangen ✔ Department of Gynecology, Obstetrics and Mammology ✔ BookingHealth.com
Vascular endothelial growth factor (VEGF) is a potent angiogenic factor for many malignant neoplasms exerting its function through activation of specific membrane receptors, that is, KDR/flk-1, residing in endothelial cells. Several recent reports indicate that VEGF receptors are also expressed in cancer cells, suggesting that specific VEGF-originated cancer cell reactions may parallel the endothelial response. Using a novel monoclonal antibody, recognizing the activated (phosphorylated) form of the KDR receptor (pKDR), we assessed the expression of pKDR in normal and malignant endometrium. A strong and consistent cytoplasmic and nuclear pKDR expression was noted in the normally cycling endometrium, including epithelial, stromal and endothelial cells, suggesting a role in the normal menstrual cycle. Approximately, one-third of the 70 stage I endometrioid adenocarcinomas analysed exhibited an intense cytoplasmic and nuclear pKDR expression in both cancer cells and peritumoral vessels. It was noted that
Endometrial Cancer Click Image to Enlarge What is endometrial cancer? The lining of the uterus is called the endometrium. Cancer of the endometrium, the most common cancer of the female reproductive organs, is a disease in which malignant (cancerous) cells are found in the endometrium. Endometrioid cancer is a specific type of endometrial cancer. Cancer of the endometrium is different from cancer of the muscle of the uterus, which is called uterine sarcoma. About 80 percent of all endometrial cancers ar...
Introduction: Endometrial carcinoma ranks 3rd in India among gynecological malignancies. Endometrial cancer (EC) can be classified into two distinct groups - type I and type II, based on histology, which differs in molecular, clinical and histopathological profiles. Type II is nonestrogen dependent, nonendometrioid, more aggressive and carries poor prognosis. Although type II cancers contribute only about 10% of EC incidence, they present at advanced age and cause approximately 50% recurrence and deaths with a low 5‑year, overall survival rate. Type II EC are also characterized by genetic alterations in p53, human epidermal growth factor‑2/neu, p16 and E‑cadherin. Materials and Methods: Endometrial carcinomas diagnosed from endometrial biopsies and hysterectomy specimens received in the Department of Pathology, Kasturba Medical College, Mangalore, from January 2007 to June 2012 were included in the study. Clinicopathological analysis of the 84 cases of EC was done with emphasis on ...
Adenocarcinoma of the endometrium is the commonest histological subtype of endometrial cancer and accounts for up to 90% of such cases 1. Pathology Histological sub types endometrioid carcinoma serous type adenocarcinoma of the endometrium ...
Inclusion Criteria: - Patients must have platinum-sensitive, recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancer. Submission of BRCA testing results is required for all patients. Patients with other (clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma) high-grade histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory. Due to the long acceptance of germline BRCA testing through Myriad, Myriad testing reports will be accepted without additional documentation. If testing for germline BRCA is done by other organizations, in addition to the testing report, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) detailing the laboratory results is required. Please retain a copy of all ...
Mamat, Suhana (2011) Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications. Cancer science, 102 (4). pp. 903-908. ISSN 1347-9032 Md Aris, Mohd Aznan and Draman, Samsul and Abdullah, Nor Zamzila and Mohd Rus, Razman and Khattak, Muhammad Muzaffar Ali Khan (2011) Serum adiponectin status among metabolic syndrome in Kuantan,Pahang. In: 15th Malaysian Family Medicine Scientific Conference , 23-26 June 2011, Seremban, Malaysia. (Unpublished) Md Aris, Mohd Aznan and Draman, Samsul and Abdullah, Nor Zamzila and Mohd Rus, Razman and Khattak, Muhammad Muzaffar Ali Khan (2011) Serum adiponectin status among metabolic syndrome in Kuantan,Pahang. In: 10th Continuing Professional Development (CPD) Series: Diabetic Asia 2011 Conference and Workshop, 6-9th October 2011, Kuala Lumpur, Malaysia. (Unpublished) Muhammad, Siti Aesah @ Naznin and Jantan, Abdul Wahab and Mat Zain, Nora and Abdul Rahman, Suzanah and Mohamed, Zulaiha and Abdul Rahim, Aidil Faszrul ...
One-carbon metabolism dietary factors, including levels of folate, choline, methionine, vitamin B2, vitamin B6 or vitamin B12, do not effect the endometrial incidence(4). But in Type I and II endometrial cancer study, intake of use of supplements containing folate and vitamins B2, B6, and B12 was associated with an increased risk of type II endometrial cancer.(5). The Folate (FOL) mediated poly-lactide-co-glycolide-polyethylene glycol nanoparticles (FOL-PEG-PLGA NPs) bearing paclitaxel (PTX), was found to be effective in indcution of cytotoxicity against HEC-1A cancer cells in vitro and in vivo, through possibly induced apoptosis(6). The joint study of the effects of dietary folate and other methyl-related nutrients, as well as three polymorphisms of MTHFR (677C,T, 1298A,C, and 1793G,A), on endometrial cancer risk among women between the ages of 30 and 69 years in urban Shanghai, China, showed an inverse association of folate intake and risk of endometrial cancer and modufied effects in women ...
Purpose: An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle factors by histologic subtype in the Ovarian Cancer Cohort Consortium (OC3).. Patients and Methods: Among 1.3 million women from 21 studies, 5,584 invasive epithelial ovarian cancers were identified (3,378 serous, 606 endometrioid, 331 mucinous, 269 clear cell, 1,000 other). By using competing-risks Cox proportional hazards regression stratified by study and birth year and adjusted for age, parity, and oral contraceptive use, we assessed associations for all invasive cancers by histology. Heterogeneity was evaluated by likelihood ratio test.. Results: Most risk factors exhibited significant heterogeneity by histology. Higher parity was most strongly associated with endometrioid (relative risk [RR] per birth, 0.78; 95% CI, 0.74 to 0.83) and clear cell (RR, 0.68; 95% CI, 0.61 to 0.76) ...
I also do not procreation has not to date filtered into American law or legal scholarship. Gastrointestinal Cancer Surgery Melanoma / Sarcoma Pancreatic / Liver uterus); Cancer: Kidney uterus fibroid pregnancy pregnancy milk palmitate vitamin and Urinary Tract; Cancer: Liver; Cancer: Pancreas; Oncolog.. The next three anterior menopause nausea and dizziness cycle phase prolferative pituitary hormones do not effect other endocrine The thyroid gland requires iodine to produce thyroxine (T4) which. address is in England but there are a number of co-ordinators assistants and He also worked with blood progesterone levels in an Asian. Now nestled in the nutrient-rich lining of your uterus is a microscopic ball of hundreds of Your baby resembles a tadpole more than a human but is growing fast. ovarian tumors endometrioid tumors clear cell ovarian tumors and. Even though Rosie had had severe problems with menstrual avoiding a large open incision in her abdomen and allowing her to recover. American ...
There is no evidence to suggest that estrogen decreased the disease-free interval or increased the risk for recurrence in early-stage disease.
Strengths of this investigation are its large size, the use of a validated and reproducible food frequency questionnaire (12-14), the low percentage of refusals of the subjects contacted, and the specific interest of the Italian population that has relatively high levels of alcohol (mostly wine) consumption (15). Our results do not indicate a major role of folate in ovarian cancer risk, nor a relevant interaction of folate with alcohol or with methionine or vitamin B6. These findings are in broad agreement with the available evidence from various studies, which in turn indicated inverse (5), absent (9), and direct (7, 8) relation of folate with ovarian cancer risk.. Our findings were confirmed after inclusion in the regression models of several lifestyle, reproductive, and dietary covariates, and at various levels of alcohol drinking. With reference to histologic subtypes of ovarian cancer (16), no association emerged for serous, endometrioid, and clear-cell tumors. However, the inverse relation ...
Endometrial Cancer, Read about Endometrial Cancer symptoms, causes, diagnosis, and treatment. Also read Endometrial Cancer articles about how to live with Endometrial Cancer, and more.
Posted on December 5, 2017 By News Updates Endometrial cancer This year, more than 10,000 women in the United States will die from endometrial cancer. In an interesting new study, scientists describe a new treatment strategy that they believe could increase survival rates for the disease. The researchers reveal how they successfully targeted and destroyed endometrial cancer cells in mice with an aggressive form of the […]. ...
Cancer Res. Din cele şapte cazuri de endometrioză, în două cazuri au fost evidenţiate zone cu atipii, considerate leziuni premaligne. Histopathologic aspects of the limited endometrial hyperplasias-a study concerning cases.
Kyle J. Norton The incidence of endometrial cancer among white women are higher in comparison of black. According to the statistic, the risk of endometrial cancer among women is 1 in 7000. Every year, about 40,000 women in US are diagnosed with the disease. Women who carry certain mutation genes, such as BRCA1 or the …. ...
Women with Lynch syndrome and endometrial cancer have elevated risks for several other cancers, including breast, bladder, and kidney cancers.
If this year is typical, about 58,000 women in the U.S-most of them postmenopausal and in their 60s-will learn they have endometrial cancer.
We classify endometrial cancer so that we can communicate and define each patients disease status, the potential for harm, and the likelihood that adjuvant the
The Report Endometrial Cancer - Pipeline Review, H1 2014 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz
Find info concerning Centralia College EECS degree. Whether you are considering an associates or a bachelors degree, your educational investment may pay off with a higher-paying job, or an in-house promotion.
Papillary serous carcinoma, clear cell carcinoma, and endometrioid carcinoma are the subtypes at the highest risk of recurrence ... Histologically, TCCE resembles endometrioid carcinoma and is distinct from other transitional cell carcinomas. In contrast to ... Some endometrioid adenocarcinomas have foci of mucinous carcinoma. The genetic mutations most commonly associated with ... The most frequent type of endometrial cancer is endometrioid carcinoma, which accounts for more than 80% of cases. Endometrial ...
Rahilly MA, Al-Nafussi A (1991). Uterus-like mass of the ovary associated with endometrioid carcinoma. Histopathology 18:549- ... ULM has also been reported associated to endometrial carcinoma and breast cancer. A clonal chromosome deletion 2p21 was found ...
... is overexpressed in non-small cell lung cancer and human placenta and chorionic carcinoma cells. In breast cancer, loss of ... For example, MTA3 expression is downregulated in breast cancer and endometrioid adenocarcinomas. ... "The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells". ...
Though mixed carcinomas can have any combination of cell types, mixed ovarian cancers are typically serous/endometrioid or ... Type I cancers are of low histological grade and include endometrioid, mucinous, and clear-cell carcinomas. Type II cancers are ... More typically, ovarian squamous cell carcinomas are cervical metastases, areas of differentiation in an endometrioid tumor, or ... There are five main subtypes of ovarian carcinoma, of which high-grade serous carcinoma (HGSC) is the most common. These ...
"Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma". ...
Mutations in this gene have been associated with hepatocellular carcinoma, hepatoblastomas, ovarian endometrioid ... "AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1". Nat ... "Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines". Scientific Reports. ...
15-30% of endometrioid carcinomas occur in individuals with carcinoma of the endometrium, and these patients have a better ... Endometrioid tumors account for approximately 20% of all ovarian cancers and are mostly malignant (endometroid carcinomas). ... Bakhru A, Liu JR, Lagstein A (2012). "A case of small cell carcinoma of the ovary hypercalcemic variant in a teenager". ... epithelial cells with abundant clear cytoplasm and may be seen in association with endometriosis or endometrioid carcinoma of ...
Risk factors for development of EIN and the endometrioid type of endometrial carcinoma include exposure to estrogens without ... a precursor lesion to uterine endometrioid carcinoma". Cancer Res. 58 (15): 3254-8. PMID 9699651. Mutter GL, Boynton KA, Faquin ... Some cases of EIN are first detected as residual premalignant disease in women who already have carcinoma, whereas other EIN ... Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL (March 2005). "Prediction of endometrial carcinoma by subjective ...
... is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas". Cancer Res. 65 (6): 2162-9. ... protein is a biomarker for ovarian carcinoma". Cancer Res. 63 (13): 3695-700. PMID 12839961. Drapkin R, von Horsten HH, Lin Y, ... "Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas". ... Protein Is a Biomarker for Ovarian Carcinoma". Cancer Research. 63 (13): 3695-3700. PMID 12839961. Retrieved 2012-11-28. ...
Notably, the expression of mPRγ was significantly higher in endometrioid and clear cell carcinomas, which are closely related ... and carcinomas: while mPRα is expressed at significantly higher levels than the others, an increased expression of mPRβ has ... been noticed in mucinous carcinomas when compared to the other tumor types and normal tissues. ...
... is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma". Int ...
... endometrioid, or clear cell carcinoma, Brenner tumor, granulosa cell tumor, stromal tumor, dysgerminoma, fibroma, or metastatic ... "A case of Meigs syndrome mimicking metastatic breast carcinoma". World Journal of Surgical Oncology. 7: 10. doi:10.1186/1477- ...
... as well as the more aggressive uterine papillary serous carcinoma and uterine clear-cell carcinoma. Endometrial stromal ... These include the common and readily treatable well-differentiated endometrioid adenocarcinoma, ... carcinosarcoma behaves similar to a high grade carcinoma, and it is felt to be of epithelial origin rather than true sarcoma. ... Endometrial carcinomas originate from cells in the glands of the endometrium (uterine lining). ...
... endometrioid endometrial carcinoma), as well as pleomorphic adenoma. Metaplasia Dysplasia Barrett esophagus - a columnar cell ...
... carcinoma, pancreatic ductal MeSH C04.557.470.200.025.240 - carcinoma, endometrioid MeSH C04.557.470.200.025.255 - carcinoma, ... carcinoma, ehrlich tumor MeSH C04.557.470.200.220 - carcinoma, giant cell MeSH C04.557.470.200.240 - carcinoma in situ MeSH ... carcinoma, large cell MeSH C04.557.470.200.280 - carcinoma, lewis lung MeSH C04.557.470.200.300 - carcinoma, non-small-cell ... carcinoma, bronchogenic MeSH C04.588.894.797.520.230 - carcinoma, non-small-cell lung MeSH C04.588.894.797.520.235 - carcinoma ...
... renal cell carcinoma, testicular germ cell tumors, colorectal cancer, lung cancer, bladder cancer, endometrioid endometrial ... McNeish IA, Bell S, McKay T, Tenev T, Marani M, Lemoine NR (June 2003). "Expression of Smac/DIABLO in ovarian carcinoma cells ... So far, SMAC overexpression has been observed to oppose cancer progression in head and neck squamous cell carcinoma, ... hepatocellular carcinoma, Hodgkin lymphoma, breast cancer, glioblastoma, thyroid cancer, ...
... carcinoma, endometrioid MeSH C13.371.056.630.705.398 - granulosa cell tumor MeSH C13.371.056.630.705.464 - luteoma MeSH C13.371 ... carcinoma, endometrioid MeSH C13.371.820.800.418.685.398 - granulosa cell tumor MeSH C13.371.820.800.418.685.464 - luteoma MeSH ... carcinoma, endometrioid MeSH C13.371.820.800.418.875.200.374 - endometrial stromal tumors MeSH C13.371.820.800.418.875.200.374. ... carcinoma, renal cell MeSH C13.371.820.800.820.535.585 - wilms tumor MeSH C13.371.820.800.820.535.585.220 - denys-drash ...
... carcinoma, endometrioid MeSH C19.391.630.705.398 - granulosa cell tumor MeSH C19.391.630.705.464 - luteoma MeSH C19.391.630.705 ... carcinoma, islet cell MeSH C19.344.421.500.124 - gastrinoma MeSH C19.344.421.500.249 - glucagonoma MeSH C19.344.421.500.500 - ... adrenocortical carcinoma MeSH C19.344.400.500 - multiple endocrine neoplasia type 1 MeSH C19.344.400.505 - multiple endocrine ... adrenocortical carcinoma MeSH C19.053.347.500 - adrenal cortex neoplasms MeSH C19.053.347.500.500 - adrenocortical adenoma MeSH ...
Tumors of ovarian epithelial types Serous tumor of borderline malignancy Serous carcinoma Well differentiated endometrioid ... Embryonal carcinoma and teratoma Teratoma and seminoma Choriocarcinoma and teratoma.embryonal carcinoma Others Sex cord/Gonadal ... carcinoma in situ) Specified types Tumors of one histologic type (pure forms) Seminoma Variant - Seminoma with ... Brenner tumor Nephroblastoma Paraganglioma Haematopoietic tumors Tumours of collecting ducts and rete Adenoma Carcinoma Tumors ...
Adenomyoma Myo-invasive endometrial endometrioid carcinoma (vs. stroma-poor adenomyosis) Low-grade endometrial stromal sarcoma ... However, both entities could coexist and the endometrial tissue within the myometrium could harbor endometrioid adenocarcinoma ...
... papillary renal cell carcinoma, papillary endometrioid carcinoma of the prostate, in thymic carcinomas, and in non-epithelial ... It can be present in: Thyroid neoplasms: It is a characteristic feature of papillary thyroid carcinoma, but has also been seen ... Breast carcinomas Vaginal, cervical and/or endometrial neoplasms Papillary neoplasms of several organs: papillary transitional ...
Unlike the more common low-grade endometrioid endometrial adenocarcinoma, USC does not develop from endometrial hyperplasia and ... Uterine serous carcinoma (USC), is an uncommon form of endometrial cancer that typically arises in postmenopausal women. It is ... UPSC is staged like other forms of endometrial carcinoma at time of surgery using the FIGO cancer staging system. Stage IA: ... Histopathologically, uterine serous carcinomas is typically characterized by (1) nipple-shaped structures (papillae) with ...
Distinction of HGSC from high-grade endometrioid carcinoma is not always possible. The progression of HGSC may also be ... Technically a 'serous carcinoma' can occur anywhere on these membranes, but high-grade serous carcinoma is generally limited to ... "TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting ... High-grade serous carcinoma (HGSC) is a type of tumour that arises from the serous epithelial layer in the abdominopelvic ...
"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers ... Uterine clear-cell carcinoma is staged like other forms of endometrial carcinoma at time of surgery using the International ... Uterine clear-cell carcinoma (CC) is a rare form of endometrial cancer with distinct morphological features on pathology; it is ... Like uterine papillary serous carcinoma CC does not develop from endometrial hyperplasia and is not hormone sensitive, rather ...
The other major subtypes within this group include high-grade serous, endometrioid, mucinous, and low-grade serous. The serous ... Clear cell ovarian carcinoma is one of several subtypes of ovarian carcinoma. Clear cell is a subtype of epithelial ovarian ... Within this epithelial group clear cell ovarian carcinoma makes up about 5-10%. Clear cell ovarian carcinoma was recognized as ... There are two subtypes of ovarian carcinoma - epithelial and nonepithelial; clear cell ovarian carcinoma is an epithelial ...
In 40% of cases, endometrioid tumors are found bilaterally. Endometrioid carcinoma can also arise in the endometrium. Grades 1 ... Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third ... Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN gene mutation profiles. PTEN mutations are more ... frequent in low-grade endometrial endometrioid carcinomas (67%) compared with low-grade ovarian endometrioid carcinomas (17%). ...
Micrograph of a small-cell carcinoma showing cells with nuclear moulding, minimal amount of cytoplasm and stippled chromatin. ... Endometrioid stromal sarcoma no endometrial stromal sarcoma [18][30] Undifferentiated vaginal sarcoma [18] ... these include leukemia and most forms of carcinoma in situ. Tumor is also not synonymous with cancer. While cancer is by ...
Carcinoma is confined to the corpus uteri itself. Stage II. Carcinoma involves the corpus and the cervix. Stage III. Carcinoma ... On histology, the tumors consist of adenocarcinoma (endometrioid, serous or clear cell) mixed with the malignant mesenchymal ( ... Carcinoma extends outside the true pelvis or involves the mucosa of the bladder or the rectum. A Cochrane review indicates ... As with endometrial carcinomas, the prognosis is influenced by the grade and type of the adenocarcinoma, being poorest with ...
October 2017). "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a ... High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3) " at ClinicalTrials. ... double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma ( ...
Endometrioid tumor. *Uterine papillary serous carcinoma. *Endometrial intraepithelial neoplasia. *Uterine clear-cell carcinoma ...
The term 'crypt cell carcinoma' has been used for them, and though perhaps more accurate than considering them carcinoids, has ... "carcinoma-like", to describe the unique feature of behaving like a benign tumor despite having a malignant appearance ... Hepatocellular adenoma/Hepatocellular carcinoma. Urogenital. *Renal cell carcinoma. *Endometrioid tumor. *Renal oncocytoma ...
In some types of carcinomas, Stage 0 carcinoma has been used to describe carcinoma in situ, and occult carcinomas detectable ... Some carcinomas are named for their or the putative cell of origin, (e.g.hepatocellular carcinoma, renal cell carcinoma). ... Carcinoma In situ[edit]. The term carcinoma in situ (or CIS) is a term for cells that are significantly abnormal but not cancer ... and sarcomatoid carcinoma (mixtures of spindle and giant cell carcinoma). Pleomorphic carcinoma contains spindle cell and/or ...
Hepatocellular adenoma/Hepatocellular carcinoma. Urogenital. *Renal cell carcinoma. *Endometrioid tumor. *Renal oncocytoma ...
Microscopic appearance is signet ring cell carcinoma, which is tumor cells with mucin droplet that displaces the nucleus to one ... particularly breast and lung carcinoma.[1] It is not associated with H. pylori infection or chronic gastritis. The risk factors ... Hepatocellular adenoma/Hepatocellular carcinoma. Urogenital. *Renal cell carcinoma. *Endometrioid tumor. *Renal oncocytoma ...
Endometrioid tumor. *Uterine papillary serous carcinoma. *Endometrial intraepithelial neoplasia. *Uterine clear-cell carcinoma ...
Endometrioid tumor. *Uterine papillary serous carcinoma. *Endometrial intraepithelial neoplasia. *Uterine clear-cell carcinoma ...
Sipple JH (1961). "The association of pheochromocytoma with carcinoma of the thyroid gland". Am. J. Med. 31: 163-6. doi:10.1016 ... In 1959 Hazard et al. described medullary (solid) thyroid carcinoma. In 1961 Sipple described a combination of a ... Micrograph of a medullary thyroid carcinoma, as may be seen in MEN 2A and MEN 2B. H&E stain. ... In 1966 Williams et al. described the combination of mucosal neuromas, pheochromocytoma and medullary thyroid carcinoma. ...
Wu W, Lin Z, Zhuang Z, Liang X (February 2009). "Expression profile of mammalian microRNAs in endometrioid adenocarcinoma". ... "Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells ...
"B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma". The Journal of Experimental ... is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration". ... "B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival". Proceedings ...
A case of combined small cell lung carcinoma featuring components of FA and cells resembling those from carcinoid tumor has ... Mardini G, Pai U, Chavez AM, Tomashefski JF (March 1994). "Endobronchial adenocarcinoma with endometrioid features and ... June 1996). "p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas". Hum. Pathol. 27 (6): 542-6. doi: ... November 2008). "[Clinicopathologic study of pulmonary adenocarcinoma with features of bronchioloalveolar carcinoma]". Zhonghua ...
NOS Endometrioid carcinoma, NOS Endometrioid cystadenocarcinoma M8381/0 Endometrioid adenofibroma, NOS Endometrioid ... NOS Reserve cell carcinoma Round cell carcinoma Small cell neuroendocrine carcinoma M8042/3 Oat cell carcinoma (C34._) M8043/3 ... Renal cell carcinoma, spindle cell M8319/3 collecting duct carcinoma (C64.9) Bellini duct carcinoma Renal carcinoma, collecting ... NOS Condylomatous carcinoma Verrucous squamous cell carcinoma Verrucous epidermoid carcinoma Warty carcinoma M8052/0 Squamous ...
PFTEC stands for Primary Fallopian Tube Endometrioid Carcinoma. PFTEC is defined as Primary Fallopian Tube Endometrioid ... How is Primary Fallopian Tube Endometrioid Carcinoma abbreviated? ... www.acronymfinder.com/Primary-Fallopian-Tube-Endometrioid-Carcinoma-(PFTEC).html,PFTEC,/a,. ... www.acronymfinder.com/Primary-Fallopian-Tube-Endometrioid-Carcinoma-(PFTEC).html ...
... Catharina C ... K. Hemminki, L. Aaltonen, and X. Li, "Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma," ... "PTEN as a molecular marker to distinguish metastatic from primary synchronous endometrioid carcinomas of the ovary and uterus ... B. C. Sheu, H. H. Lin, C. K. Chen, K. H. Chao, C. T. Shun, and S. C. Huang, "Synchronous primary carcinomas of the endometrium ...
What is endometrioid carcinoma? Meaning of endometrioid carcinoma medical term. What does endometrioid carcinoma mean? ... Looking for online definition of endometrioid carcinoma in the Medical Dictionary? endometrioid carcinoma explanation free. ... endometrioid carcinoma. Also found in: Dictionary, Thesaurus, Encyclopedia.. Related to endometrioid carcinoma: endometrial ... The histologic types included 36 serous carcinomas, 10 mucinous carcinomas, 11 endometrioid carcinomas, 5 clear cell neoplasms ...
3 The abbreviations used are: EC, endometrial carcinoma; NEEC, nonendometrioid carcinoma; EEC, endometrioid carcinoma; FISH, ... 4 of 15 clear cell carcinomas and 3 of 24 serous carcinomas) but not in the 7 mucinous and endometrioid carcinomas. The ... Endometrial carcinoma (EC) comprises at least two types of cancer: endometrioid carcinomas (EECs) are estrogen-related tumors, ... We used 24 endometrioid carcinomas that had been previously pathologically and molecularly characterized (5) and 11 NEECs (4 ...
Regulatory mechanism of IGFBP-3 expression in ovarian endometrioid carcinoma. Pao-Ling Torng, Ching-Wei Lin, Su-Cheng Huang and ... Regulatory mechanism of IGFBP-3 expression in ovarian endometrioid carcinoma. Pao-Ling Torng, Ching-Wei Lin, Su-Cheng Huang and ... Regulatory mechanism of IGFBP-3 expression in ovarian endometrioid carcinoma. Pao-Ling Torng, Ching-Wei Lin, Su-Cheng Huang and ... Regulatory mechanism of IGFBP-3 expression in ovarian endometrioid carcinoma Message Subject (Your Name) has forwarded a page ...
The low rate of POLE mutations in ovarian endometrioid carcinoma and their predominance within the low FIGO grade tumors are in ... The prevalence and patterns of POLE mutated tumors in endometrioid carcinomas of the ovary, however, have not been studied in ... Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. Hoang, L.N., McConechy, M.K., Köbel, M., ... we investigate the frequency of POLE exonuclease domain mutations in a series of 89 ovarian endometrioid carcinomas. ...
Diagnosis of grade 1 endometrioid endometrial carcinoma without the presence of one of the 3 criteria mentioned in inclusion ... Endometrioid Endometrial Carcinoma. Complex Atypical Hyperplasia. Levonorgestrel Intrauterine Device. Endometrial Biopsy. ... Diagnosis of grade 2 endometrioid endometrial carcinoma or higher on endometrial biopsy or on dilation and curettage specimen. ... and Grade 1 Endometrioid Endometrial Carcinoma (G1EEC). The safety and scientific validity of this study is the responsibility ...
This subtype of endometrioid adenocarcinoma consists of finger-like (...) ... Home , E. Pathology by systems , Reproductive system , Female genital system , Uterus , villoglandular endometrioid carcinoma ... Focal villoglandular changes are seen in almost 25% of endometrioid carcinomas. Villoglandular variants have to be ... Definition : This subtype of endometrioid adenocarcinoma consists of finger-like projections lined by tall columnar cells with ...
Endometrioid" by people in this website by year, and whether "Carcinoma, Endometrioid" was a major or minor topic of these ... "Carcinoma, Endometrioid" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Carcinoma, Endometrioid" by people in Profiles. ... It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of ...
... Gynecol ... Grade 3 endometrioid cancers (G3 EEC), share features of type 1 and type 2 cancer and have not been classified as either. This ... Objective: Endometrial cancer is classified into: Type I estrogen-dependent endometrioid adenocarcinoma, with good prognosis ... and clear cell carcinoma (CC), sarcoma, carcinosarcoma and endometrial tumors of mixed histology. 131 (84%) datasets were ...
... in endometrial simple hyperplasia and endometrioid carcinoma. - Dimple Chakravarty, Radhika Srinivasan, Sujata Ghosh, Arvind ... Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma.. Abstract. AIMS: The aim of this ... Decreased expression of ERbeta, ERalpha, and progesterone receptor proteins was observed in endometrioid carcinoma compared ... Thus, ERbeta alterations are important in endometrioid carcinoma. The relationship of ERbeta expression to myoinvasion warrants ...
One fallopian tube carcinoma was mixed with serous carcinoma. In 4 cases, there was also an endometrioid carcinoma involving ... and 1 patient died of metastatic endometrial carcinoma (at 9 mo). Simultaneous endometrioid carcinomas of the uterus and FT are ... Endometrioid Carcinoma Simultaneously Involving the Uterus and the Fallopian Tube: A Clinicopathologic Study of 13 Cases. ... According to the FIGO grading of the endometrial endometrioid carcinomas, the cases were distributed as follows: Grade 1 (3) ...
Overweight and obesity do not determine worst prognosis in endometrioid endometrial carcinoma. Zeitschrift:. Archives of ... Overweight and obesity do not determine worst prognosis in endometrioid endometrial carcinoma ... Int J Gynaecol Obstet 105:103-104 CrossRef Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and ... Zurück zum Zitat Gates EJ, Hirschfield L, Matthews RP, Yap OWS (2006) Body mass index as a prognostic factor in endometrioid ...
... endometrioid (LGEC)] and type II (high-grade, nonendometrioid; refs. 1, 2). Endometrioid endometrial carcinomas are thought to ... Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma. Lorena Lazo de la Vega, Mia C. ... Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma. Lorena Lazo de la Vega, Mia C. ... Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma. Lorena Lazo de la Vega, Mia C. ...
... ultrasound and intraoperative macroscopic examination for assessing myometrial infiltration in low risk endometrioid carcinoma ... observational study comprising women with preoperative diagnosis of well or moderately differentiated endometrioid carcinoma of ... ultrasound and intraoperative macroscopic examination for assessing myometrial infiltration in low risk endometrioid carcinoma ... ultrasound and intraoperative macroscopic examination for assessing myometrial infiltration in low risk endometrioid carcinoma ...
... and Endometrioid Endometrial Carcinoma (EEC) are two lethal diseases of public health importance worldwide. Understanding the ... Hepatocellular Carcinoma (HCC) and Endometrioid Endometrial Carcinoma (EEC) are two lethal diseases of public health importance ... Comparative genetic and transcriptome analyses of Hepatocellular Carcinoma and Endometrioid Endometrial Carcinoma highlight ...
Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am J Surg ... The Haphazard Pattern in Grade-3 Endometrioid Carcinoma Is Associated with Poor Prognosis and Tumor Lymphocyte Infiltration. ... The Haphazard Pattern in Grade-3 Endometrioid Carcinoma Is Associated with Poor Prognosis and Tumor Lymphocyte Infiltration ... mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. ...
Expression of ERbeta2/betacx was decreased in endometrioid carcinoma as compared to proliferative endometrium (P , 0.01). A ... and 26 endometrioid carcinomas. The transcript and protein levels were determined by semiquantitative reverse transcriptase- ... was to analyze the expression of ERbeta1 and ERbeta2/betacx isoforms in nonneoplastic endometrium and endometrioid carcinoma. ... Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma.. @article{ ...
The aim of this study was to evaluate the prognostic value of HIF-1α and p27kip expression in patients with endometrioid ... In patients with endometrioid endometrial cancer, necrosis and necrosis-related expression of HIF-1α are important prognostic ... Immunohistochemical staining of HIF-1α, CAIX, Glut-1 and p27 kip1 in endometrioid endometrial carcinoma. Typical patterns are ... From: Necrosis related HIF-1α expression predicts prognosis in patients with endometrioid endometrial carcinoma ...
In endometrioid carcinomas, the fascin expression profile is less defined, and the significance of CD44v6 is uncertain. We ... Fascin and CD44v6 expressions were evaluated, individually and in combination, in a series of 47 endometrioid carcinomas and 10 ... The expression rates of fascin and CD44v6 in endometrioid carcinoma were 72.34% and 46.80%, respectively. Although these ... On the other hand, CD44v6 was not a predictive factor in endometrioid cancer. The virtual slide(s) for this article can be ...
In this study, we investigated clinical and prognostic role of miRNA-205 in endometrioid endometrial cancer. After total RNA ... with endometrioid endometrial cancer being the most frequent type. Despite the relatively favourable prognosis in cases of ... Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma. Gynecol Oncol. 2014 Mar;132(3): ... Carcinomas Is the Subject Area "Carcinomas" applicable to this article? Yes. No. ...
Endometrioid Adenocarcinoma Patient Info: Diagnosed: over 5 years ago, Female, Age: 51, Stage II ...
5-year survival rate of patients with simple type ovarian endometrioid carcinoma and mixed type ovarian endometrioid carcinoma ... our data displayed 14 cases of ovarian endometrioid carcinoma combining with endometrioid carcinoma, accounting for 45.2%, ... indicating ovarian endometrioid carcinoma was easy intercurrent double carcinoma. The main clinical manifestations of the ... treatment and prognostic of ovarian endometrioid carcinoma, the clinical data of 36 patients with ovarian endometrioid ...
... the slide shows nests of Grade 1 endometrioid carcinoma extending deep into the myometrium, along with very focal ... Endometrioid adenocarcinoma is the most common malignancy of the uterine endometrium. It typically occurs in perimenopausal and ...
The squamous component of one of the high-grade carcinomas showed genetic abnormalities similar to those of endometrioid ... The squamous component of one of the high-grade carcinomas showed genetic abnormalities similar to those of endometrioid ... The squamous component of one of the high-grade carcinomas showed genetic abnormalities similar to those of endometrioid ... The squamous component of one of the high-grade carcinomas showed genetic abnormalities similar to those of endometrioid ...
Molecular profiling and molecular classification of endometrioid ovarian carcinomas Paulina Cybulska 1 , Arnaud Da Cruz Paula 1 ... Molecular profiling and molecular classification of endometrioid ovarian carcinomas Paulina Cybulska et al. Gynecol Oncol. 2019 ... Objective: Endometrioid ovarian carcinomas (EOCs) comprise 5-10% of all ovarian cancers and commonly co-occur with synchronous ... PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. Marchiò C, De Filippo MR, Ng CK, ...
54 patients with clinical Stage I and II endometrioid carcinoma of the endometrium, representing 3.5% of all such patients, ... From 1975 to 1992, 54 patients with clinical Stage I and II endometrioid carcinoma of the endometrium, representing 3.5% of all ... Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the ... Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the ...
Hereby presented is a case of papillary endometrioid carcinoma of intermediate grade with invasion in leiomyoma, expressed via ... Although the intermediate grade papillary endometrioid adenocarcinoma of the endometrium is currently not included in the ... its existence provokes an interest due to the necessity to perform differential diagnosis against other endometrioid tumors. ... In endometrioid cancer cases, the depth of myometrial invasion, the lymphovascular space invasion (LVSI) and the microcystic, ...
Hormone therapy using medroxyprogesterone may be effective in treating endometrioid cancer.PURPOSE: This phase II trial is ... recurrent endometrial carcinoma. *stage I endometrial carcinoma. *stage II endometrial carcinoma. *stage III endometrial ... receptor-negative endometrioid adenocarcinoma of the uterine corpus.. - Determine the early and late changes in gene expression ... Histologically confirmed primary endometrioid adenocarcinoma of the uterine corpus. - All histologic grades and stages eligible ...
Expression of ERβ2/βcx was decreased in endometrioid carcinoma as compared to proliferative endometrium (P, 0.01). A ... Estrogen receptor β1 and the β2/βcx isoforms in nonneoplastic endometrium and in endometrioid carcinoma ... Estrogen receptor β1 and the β2/βcx isoforms in nonneoplastic endometrium and in endometrioid carcinoma ... and 26 endometrioid carcinomas. The transcript and protein levels were determined by semiquantitative reverse transcriptase- ...
  • Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. (thefreedictionary.com)
  • They are unrelated to estrogen exposure and develop from atrophic endometrium through the so-called endometrial intraepithelial carcinoma. (aacrjournals.org)
  • The low rate of POLE mutations in ovarian endometrioid carcinoma and their predominance within the low FIGO grade tumors are in contrast to the findings in the endometrium. (fluidigm.com)
  • The aim of this study was to analyze the expression of estrogen receptor (ER) beta in endometrioid carcinoma in comparison to non-neoplastic endometrium. (curehunter.com)
  • Although the simultaneous presentation of endometrial and ovarian carcinomas of the endometrioid type is well described, little is known about a similar phenomenon involving the endometrium and fallopian tube (FT). We present the clinicopathologic features of 13 such cases seen in the Department of Pathology at The University of Texas M.D. Anderson Cancer Center over an 8 year period (1995 to 2002). (ovid.com)
  • One single center observational study comprising women with preoperative diagnosis of well or moderately differentiated endometrioid carcinoma of the endometrium. (cun.es)
  • Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. (semanticscholar.org)
  • Fascin and CD44v6 expressions were evaluated, individually and in combination, in a series of 47 endometrioid carcinomas and 10 proliferative endometrium samples. (biomedcentral.com)
  • Endometrioid adenocarcinoma is the most common malignancy of the uterine endometrium. (utoronto.ca)
  • From 1975 to 1992, 54 patients with clinical Stage I and II endometrioid carcinoma of the endometrium, representing 3.5% of all such patients, were deemed medically inoperable and exclusively received radiation therapy. (ndsl.kr)
  • The objective of this study was to analyze the expression of ERβ1 and ERβ2/βcx isoforms in nonneoplastic endometrium and endometrioid carcinoma. (bmj.com)
  • The study was conducted on samples of 22 proliferative endometrium, 15 secretory endometrium, 20 simple hyperplasia (without atypia), and 26 endometrioid carcinomas. (bmj.com)
  • The surface epithelial changes (SECs), typically seen in well to moderately differentiated endometrioid carcinoma of endometrium, are histologically defined by better cellular differentiation and an architectural pattern different from underlying carcinoma. (biomedcentral.com)
  • In a proteomics screen, we have identified CTH as a marker for clear cell carcinoma differentiation, as it is expressed at high levels in clear cell carcinomas of the ovary and endometrium. (ubc.ca)
  • The present study investigated the potential role of ALCAM in the transition from normal endometrium to endometrioid adenocarcinoma (EEC). (bmj.com)
  • Endometrioid carcinomas of the ovary and endometrium are both described to contain PTEN, PIK3CA, ARID1A , PPP2R1A, and CTNNB1 (9-catenin) mutations. (thefreedictionary.com)
  • Approximately 95% of these malignancies are carcinomas of the endometrium . (medscape.com)
  • Open references p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry. (humpath.com)
  • Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third of cases have focal squamous differentiation. (wikipedia.org)
  • Endometrioid carcinoma can also arise in the endometrium. (wikipedia.org)
  • The second case was moderately-differentiated endometrioid carcinoma with squamous and mucinous differentiation. (biomedcentral.com)
  • The microscopic examination showed FIGO Grade 2/3 endometrioid carcinoma with squamous and mucinous differentiation. (biomedcentral.com)
  • In the study, 63.7% of serous, 21.2% of clear cell, 11.2% of endometrioid, and 3% of mucinous ovarian (1/31) cancers were S100A1+ by immunohistochemical staining of tissue microarrays (n = 500). (umn.edu)
  • In contrast, clear-cell (26.2% vs. 4.5%), endometrioid (26.6% vs. 2.5%), and mucinous (7.5% vs. 1.2%) carcinomas were relatively more common among the low-stage versus high-stage tumors. (nih.gov)
  • Malignant epithelial ovarian tumors are currently divided into high-grade serous, low-grade serous, endometrioid, mucinous and clear cell carcinomas ( 2 ). (spandidos-publications.com)
  • The present series consisted of 39 sex-cord stromal tumors (19 thecofibromas, 16 fibromas, 2 granulosa cell tumors and 2 teratomas), 22 borderline tumors and 126 carcinomas (56 serous high-grade carcinomas, 30 endometrioid carcinomas, 18 mucinous carcinomas, 12 clear cell carcinomas, 4 serous low-grade carcinomas, 1 undifferentiated carcinoma, and 5 mixed-type carcinomas). (spandidos-publications.com)
  • Ovarian tumors can also be from three other, rarer subtypes: mucinous, endometrioid, and clear cell. (healthline.com)
  • The outlook for advanced mucinous carcinomas is usually worse than for advanced serous tumors. (healthline.com)
  • Mucinous carcinoma usually occurs in one ovary and can grow to be very large. (cancer.ca)
  • Mucinous carcinoma that has started in the ovary can be hard to tell apart from cancer that has spread (metastasized) from another part of the body to the ovary. (cancer.ca)
  • rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. (uib.no)
  • PTEN as a molecular marker to distinguish metastatic from primary synchronous endometrioid carcinomas of the ovary and uterus," Diagnostic Molecular Pathology , vol. 12, no. 2, pp. 71-78, 2003. (hindawi.com)
  • 44,46) Basically, if both tumors are low-grade endometrioid and involved sites are limited to uterine corpus and ovary, the prognosis is favorable, while type 2 (serous and clear cell) carcinomas, high-grade endometrioid carcinomas , and involvement of other stage III sites in addition to ovary portend a grave prognosis. (thefreedictionary.com)
  • The prevalence and patterns of POLE mutated tumors in endometrioid carcinomas of the ovary, however, have not been studied in detail. (fluidigm.com)
  • In 4 cases, there was also an endometrioid carcinoma involving the ovary, all of them with an intact ovarian capsule. (ovid.com)
  • We encountered two cases of endometrioid carcinoma of uterus with extensive surface epithelial changes (SECs) mimicking serous borderline tumor (SBT) of the ovary. (biomedcentral.com)
  • We encountered two cases of endometrioid carcinoma showing exuberant SECs, histologically mimicking serous borderline tumor (SBT) of ovary. (biomedcentral.com)
  • Case 1 (A - H) . Scanning power (A) showing well differentiated endometrioid carcinoma with SECs mimicking micropapillary serous borderline tumor of the ovary. (biomedcentral.com)
  • Endometrioid borderline tumours , clear cell borderline tumours and Brenner (transitional cell) borderline tumours are almost always found in one ovary. (cancer.ca)
  • Endometrial carcinoma (EC) comprises at least two types of cancer: endometrioid carcinomas (EECs) are estrogen-related tumors, which are frequently euploid and have a good prognosis. (aacrjournals.org)
  • Conversely, type II tumors are NEECs (papillary serous and clear cell carcinomas) that occur in older women. (aacrjournals.org)
  • We used 24 endometrioid carcinomas that had been previously pathologically and molecularly characterized (5) and 11 NEECs (4 clear cell and 7 serous tumors). (aacrjournals.org)
  • These POLE mutated endometrial tumors were almost exclusively of the endometrioid histotype. (fluidigm.com)
  • Clinicopathological data compared with immunohistochemistry and survival in 156 consecutive patients with poor prognosis cancer-G3 EEC, uterine papillary serous (UPSC) and clear cell carcinoma (CC), sarcoma, carcinosarcoma and endometrial tumors of mixed histology. (nih.gov)
  • FT tumors that could have represented luminal extension of the endometrial carcinoma or that represented an unequivocal metastasis to the FT were excluded. (ovid.com)
  • In the endometrioid subtype of ovarian and endometrial cancers, relapse-free survival was decreased for patients with S100A1+ tumors. (umn.edu)
  • Endometrioid carcinoma simultaneously involving ovaries as well as the uterine corpus may present a diagnostic dilemma because of the difficulty in determining whether the lesions are separate primary tumors or metastases. (ajou.ac.kr)
  • No serous or high-grade endometrioid tumors stained for either marker. (elsevier.com)
  • Now, however, new research suggests that targeting a protein that is most abundant on cancer stem cells in endometrioid tumors may offer a way forward. (medicalnewstoday.com)
  • In the Journal of Experimental Medicine , researchers from the Cleveland Clinic in Ohio explain how they investigated the immune regulatory protein CD55 and the role that it plays in cancer stem cells in endometrioid tumors. (medicalnewstoday.com)
  • After studying laboratory-grown human cells and tissue from patients, the researchers found an abundance of CD55 protein on the surface of cancer stem cells in endometrioid tumors. (medicalnewstoday.com)
  • The researchers found that high levels of CD55 protein in the stem cells of the endometrioid tumors made the cells more aggressive and caused them to develop resistance to cisplatin. (medicalnewstoday.com)
  • The new study is significant because it shows how targeting CD55 may offer a way to block both self-renewal and treatment-resistance in the stem cells of endometrioid tumors. (medicalnewstoday.com)
  • Although there are recognized differences in the type of ovarian carcinomas between those tumors diagnosed at low versus high stage, there is a lack of data on stage distribution of ovarian carcinomas diagnosed according to the current histopathologic criteria from large population-based cohorts. (nih.gov)
  • High-grade serous carcinomas accounted for 35.5% of stage I/II tumors and 87.7% of stage III/IV tumors. (nih.gov)
  • Tumors with other than endometrioid histology were excluded. (springer.com)
  • The present study analyzed 187 ovarian tumors (39 sex‑cord stromal tumors, 22 borderline tumors and 126 carcinomas) for the expression of the high‑mobility group AT‑hook 2 (HMGA2) gene, for mutations in the isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1), isocitrate dehydrogenase (NADP(+)) 2, mitochondrial (IDH2) and telomerase reverse transcriptase (TERT) genes, and for methylation of the O6‑methylguanine‑DNA methyltransferase (MGMT) promoter. (spandidos-publications.com)
  • A few of these tumors share genomic and molecular features with carcinomas ( 3 ), but it remains unclear as to whether this is a feature of only a subset or of borderline tumors in general. (spandidos-publications.com)
  • Clinically, endometrial cancers fall into 2 categories: endometrioid (type I) and serous (type II) tumors. (nih.gov)
  • The researchers found that about 25% of tumors classified by pathologists as high-grade endometrioid have a pattern of genetic alterations much like that of serous tumors. (nih.gov)
  • Surprisingly, the researchers found similarities between endometrioid and colorectal tumors as well. (nih.gov)
  • About 2 to 4 percent of ovarian tumors are endometrioid tumors. (healthline.com)
  • Endometrioid tumors are most common in women ages 50 to 70. (healthline.com)
  • The five-year survival rate for women with cancerous endometrioid tumors is 83 percent . (healthline.com)
  • Like endometrioid carcinomas, clear cell tumors can be caused by endometriosis or noncancerous tumors. (healthline.com)
  • In 40% of cases, endometrioid tumors are found bilaterally. (wikipedia.org)
  • Grade 3 endometrioid cancers (G3 EEC), share features of type 1 and type 2 cancer and have not been classified as either. (nih.gov)
  • The molecular events driving low-grade endometrioid endometrial carcinoma (LGEC) development-like in many cancers-are incompletely understood. (aacrjournals.org)
  • Endometrioid ovarian carcinomas (EOCs) comprise 5-10% of all ovarian cancers and commonly co-occur with synchronous endometrioid endometrial cancer (EEC). (cdc.gov)
  • Uterine cancers were classified by histologic type (endometrioid carcinoma, other carcinoma, carcinosarcoma, and sarcoma). (cdc.gov)
  • The majority of endometrial cancers is early stage and of the endometrioid histological type, as the symptoms (mainly vaginal bleeding) of the disease lead to an early diagnosis. (openrepository.com)
  • However, it seems that some endometrioid tumours share similar clinical features as type II cancers, developing more aggressive disease, forming distant metastases and being characterised by less favourable prognosis [ 5 , 6 ]. (plos.org)
  • Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, BC, Canada Running Title: Distinct cellular origins for endometrioid and clear cell cancers Abstract Endometrial epithelium is the presumed tissue of origin for both eutopic and endometriosis-derived clear cell and endometrioid carcinomas. (ubc.ca)
  • Diagnosis of endometrial clear cell carcinomas is difficult owing to the low reproducibility of histological cell type in high-grade endometrial cancers. (elsevier.com)
  • We sought to evaluate the use of napsin A and glypican 3 staining to distinguish clear cell carcinoma from other high-grade endometrial cancers. (elsevier.com)
  • FGF/FGFR aberrations reported in cancers are mainly thought to be gain-of-function changes, and several cancers have high frequencies of FGFR alterations, including breast, bladder, or squamous cell carcinomas (lung and head and neck). (springer.com)
  • Over 80 percent of uterine cancers are endometrioid carcinomas. (medicalnewstoday.com)
  • Conclusion: In combination with clinical, pathologic, and molecular data, our results support that some endometriotic lesions may predispose to clear cell and endometrioid ovarian cancers. (aacrjournals.org)
  • Most ovarian cancers are epithelial ovarian carcinomas. (cancer.ca)
  • Endometrial cancer is classified into: Type I estrogen-dependent endometrioid adenocarcinoma, with good prognosis and type 2 non-estrogen-dependent cancer with serous or clear cell histology and poor prognosis. (nih.gov)
  • and the prognosis of gade-3 endometrioid carcinoma (G3EC). (springermedizin.de)
  • Prognosis of ovarian endometrioid carcinoma patients undergoing cytoreductive surgery early is favorable, but prognosis of those patients with endometrial cancer is poor. (oatext.com)
  • In terms of histopathology, it corresponds to endometrioid endometrial cancer (EEC) and usually consists of low grade and low stage tumours with favourable prognosis [ 2 ]. (plos.org)
  • 75% positively stained tumor cells, was significantly associated with poor prognosis and reduced disease-specific survival in endometrioid endometrial adenocarcinoma (EEA). (scilifelab.se)
  • These data suggest that S100A1 is a marker for poor prognosis of endometrioid subtypes of cancer. (umn.edu)
  • CONCLUSION This study suggests that HER-2/neu expression correlated with outcome independent of other factors in endometrial carcinoma and may aid in estimating prognosis. (semanticscholar.org)
  • Simultaneous endometrioid carcinomas of the uterus and FT are unusual and occur primarily in obese perimenopausal women. (ovid.com)
  • The study includes four ovarian cancer FIGO stage I and eight stage III/IV patients, and four patients also with independent endometrial carcinoma of the uterus. (ajou.ac.kr)
  • The Cancer Genome Atlas research network recently identified an ultramutated group of endometrial carcinomas, characterized by mutations in POLE, and exceptionally high substitution mutation rates. (fluidigm.com)
  • In this study, we investigate the frequency of POLE exonuclease domain mutations in a series of 89 ovarian endometrioid carcinomas. (fluidigm.com)
  • AJOU Open Repository: Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma. (ajou.ac.kr)
  • The purpose of this study was to determine whether mutations in the Bax gene play a role in the development of ovarian endometrioid carcinoma with a microsatellite instability phenotype. (ajou.ac.kr)
  • No mutations were found in the synchronous microsatellite instability-high ovarian endometrioid carcinoma from the same patient. (ajou.ac.kr)
  • In squamous cell carcinomas, HRAS is the predominant isoform mutated (8%), followed by KRAS (3%) and NRAS (2%) (Catalogue of Somatic Mutations In Cancer [COSMIC] database). (cancer.gov)
  • McCormick, "High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma ," Cancer Research, vol. (thefreedictionary.com)
  • Villoglandular variants have to be distinguished from the more aggressive papillary serous carcinoma . (humpath.com)
  • In 2 cases, there were also small areas of other histologic types, papillary serous carcinoma (1 case), and papillary endometrial carcinoma of intermediate grade (another case). (ovid.com)
  • These cells were arranged in papillary pattern (Figure 1A ) and classic well differentiated endometrioid adenocarcinoma (Figure 1B ). (biomedcentral.com)
  • For younger women (ages 40-45 years) whose mothers were affected with endometrial malignancies, the risk of developing endometrioid carcinoma was slightly greater than the risk of developing papillary serous cystadenocarcinoma. (wiley.com)
  • Forty-two cases, including 21 uterine papillary serous carcinomas (UPSC) and 21 age-, nuclear-grade-, and clinical-stage-matched uterine endometrioid carcinomas (UEC), were studied immunohistochemically for p53 and bcl-2 in archival paraffin-embedded tissue. (elsevier.com)
  • Other histologic subtypes include adenosquamous, clear cell, and papillary serous carcinomas. (medscape.com)
  • We analyzed a total of 60 tumor specimens, 49 ovarian endometrioid carcinomas and 11 concurrent endometrial endometrioid carcinomas from 49 patients. (ajou.ac.kr)
  • Tumor and normal-tissue specimens from eight patients with a microsatellite instability-high phenotype colorectal carcinoma were included in this study as controls. (ajou.ac.kr)
  • Undifferentiated component can be misinterpreted as solid component of high-grade endometrioid carcinoma or sarcomatous component of malignant mixed mullerian tumor. (who.int)
  • Particularly, serous tubal intraepithelial carcinoma (STIC), a noninvasive tumor lesion formed preferentially in the distal fallopian tube epithelium, was proposed as a precursor for HGSC. (mdpi.com)
  • Metaplastic breast carcinoma is a rare entity of breast cancer expressing epithelial and/or mesenchymal tissue within the same tumor. (biomedcentral.com)
  • They are part of the surface epithelial tumor group of ovarian neoplasms (10-20% of which are the endometrioid type). (wikipedia.org)
  • One endometrial polyp, obtained from a case of cryopreserved endometrioid carcinoma , and 9 frozen archived endometrioid endometrial carcinomas were also analyzed by immunohistochemistry in order to examine expression of CD117 in malignant endometria, as well as to identify suitable cases for CD117 immunoprecipitation and Western blot analysis (selection criteria and blotting methodology are described below). (thefreedictionary.com)
  • Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endom. (cdc.gov)
  • Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma. (scilifelab.se)
  • Vaginal and pelvic recurrences in stage I and II endometrial carcinoma--survival and prognostic factors. (openrepository.com)
  • In this study, we investigated clinical and prognostic role of miRNA-205 in endometrioid endometrial cancer. (plos.org)
  • Wilczynski M, Danielska J, Dzieniecka M, Szymanska B, Wojciechowski M, Malinowski A (2016) Prognostic and Clinical Significance of miRNA-205 in Endometrioid Endometrial Cancer. (plos.org)
  • For endometrial carcinoma, prognostic stratification methods do not satisfactorily identify patients with adverse outcome. (scilifelab.se)
  • OBJECTIVE: To evaluate interobserver reproducibility of histologic grade in endometrial adenocarcinomas of endometrioid type (EC), to assess the relationships between nuclear grade and the amount of argyrophilic nucleolar organizer region (AgNOR) proteins and to determine the prognostic value of AgNOR proteins and the main clinicopathologic parameters. (elsevier.com)
  • OBJECTIVE We previously described vascular invasion-associated changes, defined as the presence of vascular invasion or perivascular lymphocytic infiltrates, as key prognostic indicators in stage I endometrioid carcinoma. (semanticscholar.org)
  • The current study was undertaken to examine the prognostic value of HER-2/neu expression in relation to other factors, including vascular invasion-associated changes, in surgical stage I endometrioid carcinoma. (semanticscholar.org)
  • STUDY DESIGN Seventy-one patients with surgical stage I endometrioid carcinoma treated by hysterectomy and followed up were randomly chosen for retrospective analysis of prognostic indicators including standard clincopathologic features, deoxyribonucleic acid ploidy, and HER-2/neu expression. (semanticscholar.org)
  • Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer. (springer.com)
  • Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. (springer.com)
  • The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. (springer.com)
  • S100P is Overexpressed in Squamous Cell and Adenosquamous Carcinoma Subtypes of Endometrial Cancer and Promotes Cancer Cell Proliferation and Invasion. (cancerindex.org)
  • Clear cell carcinomas are the rarest of the three subtypes. (healthline.com)
  • Methods/Materials Twenty cases of pure and mixed endometrial clear cell carcinoma were extracted from the 2000-2014 archival material in the Departments of Obstetrics & Gynecology and Pathology at Montefiore Medical Center and compared to serous and grade 3 endometrioid controls. (elsevier.com)
  • Approximately eighty percent of endometrial carcinomas are endometrioid adenocarcinomas. (medscape.com)
  • However, HPV-18 DNA was more prevalent in adenocarcinomas than in squamous cell carcinomas of the cervix. (aacrjournals.org)
  • Therefore, letrozole in this study be investigated prospectively and evaluated as maintenance therapy after standard surgical and chemotherapy treatment in comparison to placebo (which is the current standard maintenance treatment) in subjects with primary, ER-positive low or high grade serous or endometrioid epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) of FIGO Stage II-IV, whose cancer has not progressed by the end of the platinum-based chemotherapy. (clinicaltrials.gov)
  • Cancerous epithelial tumours are also called epithelial ovarian carcinomas, and the different types have carcinoma as part of their name. (cancer.ca)
  • Serous carcinoma is the most common type of cancerous epithelial tumour. (cancer.ca)
  • Undifferentiated carcinoma refers to tumours that start in epithelial cells but cannot be grouped into any type of epithelial ovarian carcinoma. (cancer.ca)
  • They tend to grow and spread more quickly than the other types of epithelial ovarian carcinoma. (cancer.ca)
  • Compare the efficacy of medroxyprogesterone, in terms of induction of histologic response, in patients with progesterone receptor-positive vs progesterone receptor-negative endometrioid adenocarcinoma of the uterine corpus. (knowcancer.com)
  • Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas," Clinical Cancer Research , vol. 4, no. 11, pp. 2577-2583, 1998. (hindawi.com)
  • On the other hand, CD44v6 was not a predictive factor in endometrioid cancer. (biomedcentral.com)
  • This narrative review investigated the possible mechanisms of early recurrence in patients with endometrioid endometrial cancer as well as the further management of them. (openrepository.com)
  • Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer. (openrepository.com)
  • We evaluated whether an immunohistochemical marker panel could reliably assess endometrioid endometrial cancer (EEC) outcome independent of clinicopathological information. (chalmers.se)
  • Endometrial cancer is one of the most common malignancies of the reproductive female tract, with endometrioid endometrial cancer being the most frequent type. (plos.org)
  • The nationwide Swedish Family-Cancer Database, which includes 10.3 million individuals and 20,974 ovarian carcinomas, was used to calculate standardized incidence ratios and 95% confidence intervals for age- and histology-specific ovarian malignancies in women whose parents or siblings were affected with malignancies at the most common disease sites. (wiley.com)
  • Background: In endometrioid endometrial cancer (EEC), current clinical algorithms do not accurately predict patients with lymph node metastasis (LNM), leading to both under- and over-treatment. (elsevier.com)
  • This phase II trial studies how well enzalutamide, carboplatin, and paclitaxel work in treating patients with endometrioid endometrial cancer that is stage III-IV or has come back (recurrent). (cancer.gov)
  • Androgens can cause the growth of endometrioid endometrial cancer. (cancer.gov)
  • Giving enzalutamide, carboplatin, and paclitaxel may work better in treating patients with endometrioid endometrial cancer. (cancer.gov)
  • High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC), is the most common and deadliest type of ovarian cancer. (mdpi.com)
  • We reviewed full slide sets of 1009 cases of 2555 patients diagnosed with ovarian carcinoma that were referred to the British Columbia Cancer Agency over a 16-year period (1984 to 2000). (nih.gov)
  • Previous TCGA research showed that a form of ovarian cancer (high-grade serous ovarian carcinoma) and a subtype of breast cancer (basal-like breast cancer) share many genomic features. (nih.gov)
  • However, three studies (13 , 14 , 15) , including the worldwide study of invasive cervical cancer (15) , showed that HPV DNA was found as frequently in ACIS or AC as in squamous cell carcinoma of the cervix. (aacrjournals.org)
  • Results: Endometriosis seemed to predispose to the development of ovarian cancer, with the association restricted to endometrioid or clear cell malignancies. (aacrjournals.org)
  • It also remains unclear whether the predisposition toward ovarian cancer applies to all histologies or is limited to endometrioid and clear cell carcinoma as suggested in some small clinical series ( 5 , 7 , 10 , 11 ). (aacrjournals.org)
  • Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial carcinoma patients. (thefreedictionary.com)
  • The clinical importance of this pathological entity is the underlying risk of carrying a concomitant genital cancer or risk of progression to endometrial carcinoma during the follow-up. (thefreedictionary.com)
  • Early mutational activation of the c-Ki ras oncogene in endometrial carcinoma , Cancer Res. (thefreedictionary.com)
  • Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study. (uib.no)
  • The most frequent type of endometrial cancer is endometrioid carcinoma, which accounts for more than 80% of cases. (wikipedia.org)
  • There is an association with endometriosis and concurrent primary endometrial carcinoma (endometrial cancer). (wikipedia.org)
  • Follow-up ranging from 6 to 54 months was available in 10 patients: 1 patient died of disease (at 38 mo), 1 patient is alive with disease (at 9 mo), 7 patients have no evidence of disease (6 to 54 mo), and 1 patient died of metastatic endometrial carcinoma (at 9 mo). (ovid.com)
  • Metastatic renal cell carcinoma to the breast is very rare, especially for clear cell carcinoma. (humpath.com)
  • and endometrioid carcinoma was found to be associated with endometrial, ovarian, and prostate malignancies and with melanoma. (wiley.com)
  • and type II includes patients with rapidly growing high-grade serous carcinoma (HGSC), high-grade endometrioid carcinoma, undifferentiated carcinomas, and highly aggressive malignancies [ 12 ]. (biomedcentral.com)
  • Five or more years after the diagnosis of endometriosis, the RRs (95% CIs) were 2.53 (1.19-5.38) for endometrioid (7 exposed cases) and 3.37 (1.24-9.14) for clear cell (4 exposed cases) malignancies. (aacrjournals.org)
  • Diagnosis of grade 1 endometrioid endometrial carcinoma without the presence of one of the 3 criteria mentioned in inclusion criteria 1. (clinicaltrials.gov)
  • Diagnosis of grade 2 endometrioid endometrial carcinoma or higher on endometrial biopsy or on dilation and curettage specimen. (clinicaltrials.gov)
  • With the progress of pathologic diagnosis technology, more and more patients with ovarian endometrioid carcinoma are detected early. (oatext.com)
  • AJOU Open Repository: Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis. (ajou.ac.kr)
  • The median age of patients at the diagnosis of endometrial carcinoma is 63 years [8]. (thefreedictionary.com)
  • Further investigation of endometrial clear cell carcinoma is needed to identify additional diagnostic tools for this rare histology. (elsevier.com)
  • The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. (springer.com)
  • Efficacy of the Levonorgestrel Intrauterine Device (IUD) to treat complex atypical hyperplasia (CAH) and grade 1 endometrioid endometrial carcinoma (G1 EEC) is defined as complete regression of disease. (clinicaltrials.gov)
  • However, in atypical hyperplasia, regardless of the level of cytologic atypia, genomic abnormalities were observed that also occurred in endometrioid carcinomas. (elsevier.com)
  • The first case was a well-differentiated endometrioid carcinoma arising in a background of complex atypical hyperplasia. (biomedcentral.com)
  • Ninety-one EMB/Cs had carcinoma, while 8 EMB/Cs showed only complex atypical hyperplasia (CAH). (cdc.gov)
  • Treatment modalities include total abdominal hysterectomy and bilateral salpingo-oopherectomy, as well as chemotherapy and radiotherapy, with regimens similar to those for endometrioid carcinoma FIGO grade 3. (thefreedictionary.com)
  • According to the FIGO grading of the endometrial endometrioid carcinomas, the cases were distributed as follows: Grade 1 (3) and Grade 2 (10). (ovid.com)
  • Hysterectomy for bleeding and biopsy-proven carcinoma. (utoronto.ca)
  • A 56 year-old female underwent total hysterectomy with bilateral salpingo-oophorectomy for uterine endometrioid carcinoma. (biomedcentral.com)
  • We identified 99 patients diagnosed with endometrioid EC and performed IHC for MMRPs MLH1, MSH2, MSH6, and PMS2 on their diagnostic EMB/C and paired hysterectomy specimen. (cdc.gov)
  • Carcinoma was identified in all 99 hysterectomy specimens. (cdc.gov)
  • Similarly, limited data from clinical reports suggest that leiomyomas occur more frequently in women undergoing hysterectomy for endometrial carcinoma ( 18 - 22 ) and perhaps sarcomas ( 19 ). (aacrjournals.org)
  • Overlap of both morphologic and molecular features between high-grade endometrioid and high-grade serous carcinomas has led some pathologists to default most of the gland-forming or near-solid, cytologically high-grade ovarian carcinomas to the serous category, to the degree that "true" high-grade endometrioid carcinomas are considered by some to be rare. (thefreedictionary.com)
  • Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. (thefreedictionary.com)
  • To investigate the clinical characteristics and relative factors of ovarian endometrioid carcinoma. (oatext.com)
  • The clinical data of 36 patients with ovarian endometrioid carcinoma were retrospectively analyzed. (oatext.com)
  • The landmark study GOG 33 described the patterns of spread in endometrial carcinoma and concluded that clinical staging is inaccurate as 22% of clinical stage I patients were assigned a higher surgical stage [1]. (thefreedictionary.com)
  • Renal clear cell carcinoma metastasis to the breast ten years after nephrectomy: a case report and literature review. (humpath.com)
  • In contrast, type II tumours occur less frequently and are represented by clear-cell and serous carcinomas. (plos.org)
  • Clear Cell and Endometrioid Carcinomas : are their differences attributable to distinct cells of origin? (ubc.ca)
  • Clear Cell and Endometrioid Carcinomas : are their. (ubc.ca)
  • Endometrial epithelium is the presumed tissue of origin for both eutopic and endometriosis-derived clear cell and endometrioid carcinomas. (ubc.ca)
  • We have since determined that other ciliated cell markers are expressed in clear cell carcinomas whereas endometrial secretory cell markers are expressed in endometrioid carcinomas. (ubc.ca)
  • Clear cell carcinoma is an IL-6 driven tumour and lineage experiments on bronchial epithelium have shown that IL-6 is an essential pathway in maintaining the population of ciliated cells. (ubc.ca)
  • Taken together we hypothesize that endometrioid carcinomas are derived from cells of secretory cell lineage whereas clear cell carcinomas are derived from cells of endometrial origin that share features with a ciliated cell lineage. (ubc.ca)
  • On the other hand, clear cell renal cell carcinoma (ccRCC) strongly deviated in terms of metabolic gene expression changes, showing widespread down-regulation. (pnas.org)
  • Common cancerous histological types associated with endometriosis are clear cell carcinoma (CCC) and endometrioid carcinoma (EC). (biomedcentral.com)
  • No cases of clear cell carcinoma that stained negative for napsin A stained positive for glypican 3. (elsevier.com)
  • No difference in the immunohistochemical profile was found between pure and mixed clear cell carcinomas and between early- and advanced-stage clear cell carcinomas. (elsevier.com)
  • Conclusions Napsin A is a more sensitive marker for endometrial clear cell carcinoma than glypican 3. (elsevier.com)
  • In histologically ambiguous cases, napsin A and glypican 3 may help distinguish clear cell carcinoma from other high-grade histologies. (elsevier.com)
  • Clear cell carcinoma is typically more aggressive. (healthline.com)
  • Clear cell carcinoma is linked to endometriosis in at least 50% of cases. (cancer.ca)
  • A common combination is clear cell carcinoma mixed with endometrioid carcinoma. (cancer.ca)
  • additionally, in 5 cases, there was an abrupt transition from nonstaining morphologically benign glands to uniformly positive p53 nuclear staining in regions of intraepithelial carcinoma. (elsevier.com)
  • It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. (umassmed.edu)
  • Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy. (openrepository.com)
  • In this case, the slide shows nests of Grade 1 endometrioid carcinoma extending deep into the myometrium, along with very focal lymphovascular invasion. (utoronto.ca)